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CHAPTER I 
 
INTRODUCTION 
 
Overview 
Vesicle associated membrane protein (VAMP), associated protein B 
(VAPB) is highly conserved type II, integral membrane protein that belongs to the 
VAP protein family. VAPs function in diverse cellular processes such as lipid 
transport and synthesis, vesicle trafficking, the unfolded protein response and 
neurotransmitter release. Genome-wide microarray analysis revealed that VAPB 
is overexpressed in human breast cancer cells lines and correlates with poor 
clinical outcome. Despite aberrant expression in human cancer, the function of 
VAPB in tumor cells is poorly understood. Our results presented herein 
investigate how VAPB regulates breast tumor cell proliferation, invasion and in 
vivo tumor growth. Specifically, we demonstrate that VAPB promotes 
proliferation, at least, in part through the AKT pathway. In addition to enhanced 
cell growth, VAPB elevates the invasive potential in breast tumor cells. We also 
identified novel VAPB interacting proteins that potentially contribute to tumor 
growth and invasion.  Moreover, our in vivo studies show that VAPB deficiency 
reduced tumor burden in the MMTV-Neu mouse model for spontaneous breast 
cancer. Collectively, these genetic, functional and mechanistic studies 
demonstrate that VAPB as a tumor-promoting factor in breast cancers. 
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VAPs: Highly conserved from yeast to mammals 
The first VAP protein (VAP-33) was identified in Aplysia californica as a 
VAMP/synaptobrevin-associated protein using a yeast two-hybrid screen (Skehel 
et al, 1995). In this study, VAP-33 was proposed to function in neurotransmitter 
release. Since the identification of VAP-33, homologs in yeast and mammals 
were discovered. The S. cerevisiae homolog of VAP-33, SCS2 was identified as 
a suppressor of inositol auxotrophy and functions in regulation of inositol 
metabolism (Nikawa et al, 1995). Two mammalian homologues (VAPA and 
VAPB) have been cloned in rat, mouse and human and share high sequence 
homology (Nishimura et al, 1999; Skehel et al, 2000; Soussan et al, 1999; Weir 
et al, 1998). VAPA and VAPB of most species share a primary organization 
consisting of three domains: a highly conserved N-terminal major sperm protein 
(MSP) domain, a coiled-coil (CC) domain, and a transmembrane (TM) domain 
(Figure 1.1B). VAPC is a splice variant of VAPB, lacking both the CC and TM 
domains. Limited data exists regarding VAPC expression and function. A VAP 
consensus sequence within the N- terminal MSP domain is conserved across 
species and isoforms as highlighted in Figure 1.1A (Kagiwada et al, 1998; 
Nikawa et al, 1995). 
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VAP Protein Domains 
 
Major Sperm Protein (MSP) Domain 
The MSP domain of VAPB is in the amino-terminus, which faces into the 
cytosol as determined by protease protection assays (Soussan et al, 1999). A 
schematic representation of VAP is shown in Figure 1.1B. Of the three structural 
components of VAP proteins (MSP, CC and TM), the MSP domain is the most 
conserved among species (Figure 1.1A), with 22% sequence homology with 
nematode MSP, a protein mediating ameboid-like motility in sperm cells (Roberts 
& Stewart, 2000) and also functions in fertility (Miller et al, 2001). The MSP 
domain of rat VAPA has a protein crystal structure similar to that of nematode 
MSP (Kaiser et al, 2005) further demonstrating protein conservation. 
The MSP domain of VAPs is an important interface for cytosolic protein 
interaction as well as targeting FFAT-motif proteins to the ER. Within the highly 
conserved VAP consensus sequence of the MSP domain is the binding site for 
FFAT-containing proteins. FFAT stands for diphenylalanine [FF] in an acidic 
tract, consisting of the amino acid consensus sequence EEFFDAxE (Loewen et 
al, 2003). This motif is a targeting signal responsible for localizing a number of 
proteins to the cytosolic surface of the endoplasmic reticulum (ER) and to the 
nuclear membrane (Kaiser et al, 2005). 
The majority of FFAT-containing proteins are involved in lipid-sensing and 
lipid transport (Lev et al, 2008). More recently, one study defined FFAT-like 
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motifs more widely than before and identified novel proteins whose functions 
have not been previously been directly linked to the endoplasmic reticulum (ER), 
such as PKA anchoring proteins (AKAPS). (Mikitova & Levine, 2012). However 
the functional significance of these new candidate FFAT-motif proteins is not well 
understood.  
 
Coiled-coil (CC) Domain 
The 50 amino acid stretch between the MSP and TM domains is predicted 
to form a coiled-coil like structure (Nishimura et al, 1999). In general, the α-helical 
coiled-coil is one of the principal dimerization motifs in proteins (Kapinos et al, 
2011). Therefore, the requirement of VAPB CC domain to facilitate dimerization 
was tested using VAPB-ΔCC mutants. While the mutant retained proper ER 
localization, it failed to interact with WT VAPB, demonstrating that the CC domain 
was necessary for VAP dimers (Kim et al, 2010). The VAP CC domain also 
resembles that of many SNARE (soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor) proteins and therefore provides a potential interface 
for VAMP proteins. 
 
Transmembrane (TM) Domain 
The TM domain is the C-terminal portion of VAPs. This domain is critical 
for localizing and docking VAPs to ER membranes. A TM domain-truncated 
mutant of VAP localized to the cytosol rather than the ER membranes. Although 
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Figure 1.1. VAP protein homology and primary 
structure (A) Multiple sequence alignment of VAP 
proteins from yeast to humans was generated by 
CLUSTALW. Residues of high conservation are 
shaded in grey. The major sperm protein (MSP) 
domain, coiled-coil (CC) domain and transmem-
brane (TM) domain are outlined in red, blue and 
green, respectively [adapted from (Lev et al, 
2008)]. (B) A schematic representation of VAP 
dimers [image taken from (Tsuda et al, 2008)].
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the GXXXG dimerization motif within the TM domain is sufficient for driving 
dimerization of TM domains alone, it is not sufficient for dimerization of full length 
VAPs (Kim et al, 2010). However, the CC domain was found to be more 
important for VAP dimerization. Thus the domains have the following order of 
importance for driving dimerization: CCD > TM > MSP (Kim et al, 2010).  
Taken together, the VAP domains play important roles in both structure 
and function by targeting cytosolic proteins to the ER (MSP), hetero- and homo-
dimerization (CC) and VAP cellular localization (TM).  
 
Cellular Functions of VAP proteins 
VAPs participate in a diverse array of cellular processes such as vesicle 
trafficking, lipid metabolism, lipid transfer, ER stress response, viral replication, 
and signal transduction [Reviewed in (Lev et al, 2008)] as suggested by the 
identification, characterization and functional analysis of VAP-interacting proteins 
in various cell types and organisms. A summary of VAP interacting proteins is 
provided in Table 1. We explore the reported VAP cellular functions below.  
 
Vesicle Trafficking 
The first VAP identified, VAP-33, provides evidence that VAPs function in 
vesicle trafficking. VAP-33 localized to plasma membrane regions of neurons and 
was proposed to function in late secretory trafficking events (Skehel et al, 1995). 
Injection of antibodies against VAP-33 inhibited synaptic transmission, 
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Table 1. Summary of VAP functions based on protein interactions.
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suggesting that VAP-33 functions in neurotransmitter release. Protein 
interactions with VAMP/synaptobrevin (Skehel et al, 1995) and several v-
SNARES and t-SNARES further implicate VAPs in vesicle docking at the plasma 
membrane (Weir et al, 2001). Along these lines, the VAP-33/SNARE interaction 
is important for insulin-dependent GLUT4 traffic (Foster et al, 2000). Other 
studies show the presence of human VAPA on TGFα-containing exocytic 
vesicles suggesting that VAPs may play a role in vesicle targeting to the plasma 
membrane (Cao et al, 2008). Furthermore siRNA-mediated depletion of both 
VAPA and VAPB inhibited trans-golgi network (TGN)-to plasma membrane 
transport (Peretti et al, 2008).  
While these results propose VAPs function in late secretory events from 
the TGN to plasma membrane, other studies show VAPs also accumulate at the 
ER-Golgi-intermediate complex (ERGIC), suggesting a role in early secretory 
vesicle trafficking events (Moumen et al, 2011; Skehel et al, 2000). The ER is the 
primary site for maturation, modification and packaging of proteins destined for 
secretion or membrane insertion (Schmidt & Stephens, 2010). Vesicle transport 
in the protein secretory pathway depends on early steps, such as the formation of 
coated vesicular intermediates, known as COPI-and COPII vesicles (Nickel & 
Rabouille, 2009). These coated vesicles are critical for the budding of vesicles 
within the ER-Golgi network and vesicle transport, both in retrograde movement 
of Golgi components back to the ER (COPI) and anterograde movement of cargo 
outward from the ER to Golgi and plasma membrane (COPII) (Spang, 2002).  
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Although Prosser et al. provide evidence that overexpression of VAPA 
blocks ER-Golgi transport by inhibiting cargo loading into COPII vesicle (Prosser 
et al, 2008), the rat homolog of VAPB, EGR-30, was shown to promote secretory 
protein transport mediated by COPI vesicles. Antibody inhibition of VAPB, 
prohibited transport between Golgi cisternae and the ER as measured by the 
accumulation of COPI coated vesicles (Soussan et al, 1999). Collectively, these 
results suggest that VAPs are involved at early and late stages of the secretory 
pathway, affecting vesicle trafficking events occurring at the ER/ Golgi network 
and the plasma membrane. 
 
Lipid Metabolism  
The yeast homolog of VAP proteins, SCS2 was originally identified as a 
suppressor of inositol auxotrophy in both cse1 and ire15 mutant strains of S. 
cerevisiae (Nikawa et al, 1995). Both mutants cannot activate the expression of 
INO1, which encodes inosotiol-1 phosphate synthase, an essential enzyme for 
myo-inositol biosynthesis is yeast cells and is also the structural basis for 
important secondary messengers such as phosphatidylinositol and its various 
phosphates (Dean & Beaven, 1989). Analysis of scs2Δ mutants, demonstrate its 
function in phospholipid biosynthesis such that scs2Δ mutants have reduced 
levels of phosphatidylinositol (Kagiwada & Zen, 2003), but other phospholipids, 
such as phosphatidylcholine, were not affected (Kagiwada & Zen, 2003).  
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Mechanistic studies revealed that SCS2 binds and sequesters a 
transcriptional repressor of INO1, known as Opi1p. Therefore, SCS2 prevents 
Opi1p’s nuclear translocation allowing for INO1 transcription (Kagiwada et al, 
1998; Nikawa et al, 1995). The dynamics of this repression are modulated by 
phosphatidic acid. Opi1p’s transcriptional repressor activity is inhibited by binding 
phosphatidic acid on the ER, facilitated by interactions with SCS2’s MSP domain. 
Since phosphatidic acid is shunted toward the production of inositol products, 
Opi1p can rapidly translocate into the nucleus in response to consumption of 
phosphatidic acid induced by inositol (Loewen et al, 2004; Loewen et al, 2003). 
Thus, the Opi1p/ SCS2 interaction is an integral part of a negative feedback 
mechanism to shut off de novo inositol lipid synthesis in the presence of 
exogenous inositol.  
 
Non-vesicular Lipid Transfer 
 The ER-localization of VAPs and its interaction with lipid transfer proteins 
(LTPs) suggest that VAPs facilitate the transfer of lipids across membranes. 
LTPs function to move hydrophobic lipids across the aqueous environment of the 
cytoplasm, using non-vesicular mediated trafficking (Wirtz, 1997). LTPs primarily 
localize membrane contact sites (MCSs), which are specialized gaps (10-20nm) 
between the ER membranes and other membrane bound organelles such as the 
mitochondria, the Golgi apparatus, endosomes, lipid droplets as well as the 
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plasma membrane (Holthuis & Levine, 2005). Thus, LTPs are hypothesized to 
modulate the lipid composition of various intracellular membranes. 
The most well-characterized VAP-LTP interactions include oxysterol 
binding protein (OSBP), Nir2 (membrane-associated phosphatidylinositol transfer 
protein 1), and ceramide transfer protein (CERT) (Amarilio et al, 2005; Peretti et 
al, 2008).  These proteins interact with VAPs through their FFAT-motif. Nir2 is a 
phosphoinositol/ phosphotidylcholine transfer protein that affects DAG levels at 
the Golgi membranes (Litvak et al, 2005). Another VAP-interacting LTP is CERT, 
which transfers newly synthesized ceramide from the ER to the Golgi for 
subsequent synthesis into sphingomyelin by SM synthase (Kumagai et al, 2005). 
OSBP, which localizes to the ER and Golgi, functions in sterol-transfer between 
the ER and Golgi apparatus and is coupled to activation of CERT (Perry & 
Ridgway, 2006).  
There is much evidence to suggest that VAPs are critical to the lipid 
transfer function of Nir2, CERT and OSBP. Using cell-free biochemical assays, it 
was shown that mutations in the FFAT motif of CERT impair its ceramide transfer 
activities, underscoring the importance of the VAP-CERT interaction in the ER 
and Golgi. Knockdown of mammalian VAPA and VAPB reduced Golgi targeting 
of Nir2, CERT, and OSBP (Litvak et al, 2005; Peretti et al, 2008). Given the lipid 
transfer functions of these proteins, the mis-targeting of these proteins affected 
the lipid composition at different MCSs such as the Golgi, as shown by reduced 
levels of PIP4, DAG and SM. Taken together, the coordinated function of LTPs 
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such as Nir2, OSBP, and CERT and VAP proteins at the ER–Golgi MCSs are 
important maintain lipid composition and thus the structural and functional 
integrity of the ER–Golgi complex (Peretti et al, 2008). 
 
The Unfolded Protein Response (UPR) 
 The UPR is an evolutionary conserved ER-stress response pathway 
activated by accumulation of misfolded proteins in the ER lumen (Walter & Ron, 
2011). In mammalian cells, there are three major UPR sensory receptors IRE1, 
ATF6, and PERK. In yeast, only IRE1 is present (Cox et al, 1993). IRE1 is an ER 
receptor with dual kinase and endonuclease activities such that upon activation, it 
initiates unconventional mRNA splicing of the transcriptional activator, Hac1p 
(Cox & Walter, 1996). In mammals Hac1p is known as XBP1 (Yoshida et al, 
2001). The yeast homolog of VAP, SCS2 was identified as a suppressor of 
inositol auxotrophy in ire15/ hac1p mutants (Nikawa et al, 1995). Moreover, 
scs2Δ mutants have increased tunicamycin-induced cell death, and reduced 
activation of IRE1, suggesting the requirement of SCS2 for UPR activation 
(Kagiwada et al, 1998). 
In mammalian cells, current data suggests that UPR receptors are 
differentially activated by VAPs. For instance, VAPB overexpression attenuates 
the ATF6-regulated transcription (Gkogkas et al, 2008). Another study 
demonstrates that VAPB expression enhances IRE1 endonuclease activity. 
Conversely, VAPB depletion attenuates this response (Kanekura et al, 2006). 
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Whether VAPB is a positive or negative regulator of the UPR remains to be 
determined. 
 
HCV Replication 
There is also evidence to suggest that VAPs function in viral replication. 
VAPA and VAPB have been shown to interact with non-structural 
phosphoproteins NS5A and NS5B of the Hepatitis C virus (HCV), which is a 
single-stranded RNA virus primarily affecting the liver (Gao et al, 2004; Tu et al, 
1999). The HCV non-structural proteins are important for viral replication 
and production (Cao et al, 2009). Studies show that VAPB neutralizing 
antibodies suppressed HCV RNA replication in a cell-free assay. Overexpression 
of full length VAPB, but not a mutant VAPB lacking the TM domain, enhanced 
NS5A and NS5B expression and HCV RNA replication in hepatocyte cell lines 
(Hamamoto et al, 2005). Knockdown of VAPB by small interfering RNA 
decreased expression of NS5B, but not of NS5A (Hamamoto et al, 2005). These 
results demonstrate the potential importance of VAPs in viral replication. 
 
Eph Receptor Signaling  
The MSP protein in C. elegans shares high sequence homology to the 
MSP domain of VAPs. In addition to nematode MSP’s intracellular function in 
cytoskeletal networks (Roberts & Stewart, 2000), the MSP protein also has 
extracellular function during fertilization, inducing oocyte maturation (Miller et al, 
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2001). Additional studies demonstrate that MSP binds to Eph-related receptor 
protein tyrosine kinase in C. elegans (VAB-1) to activate ERK/ MAPK pathways 
(Kosinski et al, 2005; Miller et al, 2003). Furthermore, Tsuda et al. has shown 
that Drosophila VAPB is cleaved, secreted and acts as a ligand for Eph receptor 
tyrosine kinases (RTKs) (Tsuda et al, 2008). Eph receptors are a highly 
conserved class of receptor tyrosine kinases that bind to ephrin ligands. Eph 
receptors have important roles in development, signal transduction and 
pathological conditions such as cancer (Pasquale, 2008; Vaught et al, 2008). 
Secreted MSP directly binds to Eph receptors and compete ephrins for binding 
(Tsuda et al, 2008). Both secreted MSP from Drosophila and human VAPB are 
able to activate Eph signaling suggesting that VAP’s extracellular signaling 
activities are evolutionarily conserved (Tsuda et al, 2008).  
 
VAPB in Human Disease 
As opposed to the restricted neuronal expression of VAP-33 in Aplysia 
californica, mammalian VAPs are ubiquitously expressed in multiple tissue types 
(Nishimura et al, 1999; Skehel et al, 2000; Soussan et al, 1999; Weir et al, 1998) 
suggesting that VAP function is not limited to neurotransmitter release, but many 
other cellular processes as described above. Moreover, there is emerging 
evidence suggesting an important role for VAPB in human disease pathologies, 
specifically neurodegenerative disorders and cancer.  
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VAPB in Amyotrophic Lateral Sclerosis (ALS) 
 A single missense mutation within the human VAPB gene is associated 
with a familial form of atypical amyotrophic lateral sclerosis (ALS). ALS is a 
progressive neurodegenerative disorder causing death in nerve cells and loss of 
motor control in patients. The identification of the P56S mutation in VAPB’s MSP 
domain and subsequent mechanistic studies has given insight into VAPB’s 
cellular function in pathological conditions (Nishimura et al, 2004).  
 Several studies have shown that expression of VAPB P56S in cell lines, 
causes insoluble protein aggregates VAPB and cytosolic mis-localization rather 
than the ER (Nishimura et al, 2004; Prosser et al, 2008). The proline residue 
resides in a highly conserved 16 amino acid stretch near the amino-terminus 
(Figure 1.1A). A proline to serine substitution causes conformational changes 
exposing VAPB’s hydrophobic patch to the cytosol, increasing the propensity for 
aggregation (Kim et al, 2010). Furthermore, VAPB P56S acts in a dominant 
negative fashion by sequestering WT VAPB (Suzuki et al, 2009).  
VAPB P56S fails to interact with FFAT-motif containing proteins, which 
mainly function in non-vesicular lipid transfer across membranes. The P56S 
VAPB mutation also disrupts calcium homeostasis affecting mitochondrial 
movement (De Vos et al, 2012), nuclear envelope (NE) architecture and 
localization of NE proteins (Tran et al, 2012). It should be noted that an additional 
mutation (T46I) in the MSP domain was identified in another patient group with 
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familial ALS, which also causes protein aggregates when expressed in cells 
(Chen et al, 2010). 
Protein inclusion bodies such as those induced by mutant VAPB are 
characteristic features of neurodegenerative disorders such as Huntington’s, 
Parkinson’s and Alzheimer’s diseases. Whether ALS disease pathogenesis is 
caused by the direct loss of VAPB function due to the dominant-negative action 
of VAPB P56S, or the mere presence of mutant protein aggregates remains to be 
determined. 
 
VAPB in Human Breast Cancer 
 Genomic abnormalities are known to function in cancer progression. In 
breast cancer alone, there are thousands of genetic aberrations (Korkola & Gray, 
2010). Interestingly, there are several reports that indicate aberrant gene 
expression of VAPB human breast cancer cells. Using genome copy number and 
gene expression analysis of both clinical breast tumor samples and breast tumor 
cell lines, it was shown that VAPB is one of 66 genes overexpressed by genomic 
copy number abnormalities (Chin et al, 2006; Neve et al, 2006). VAPB was 
amplified or overexpressed in eight out of fifty breast cancer cell lines. Notably, a 
VAPB-IKZF3 fusion protein was identified in BT474 and shown to enhance cell 
proliferation (Edgren et al, 2011). While the VAPB- expressing breast cancer cell 
lines vary in intrinsic molecular subtype, five of the eight cell lines were HER2 
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Gene Cluster ER PR HER2
MCF7 Luminal + + -
T47D Luminal + + -
HCC1428 Luminal + + -
BT474 Luminal + + +
SUM52PE Luminal + - +
UACC812 Luminal + - +
SKBR3 Luminal - - +
HCC1954 Basal A - - +
MDA MB 157 Basal B - - -
Table 2. VAPB-expressing human breast cancer cell lines. Cell 
lines are classified as luminal or basal genetic subtype, estrogen 
(ER), progesterone (PR) or HER2 positive. Results were gathered 
from microarray analysis from (Neve et al, 2006) or western analysis 
of protein lysates (Figure 1.2 D)
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gene amplified (Table 2). Interestingly, a study found recurrent amplification of 
VAPB in HER2- amplified invasive breast cancers (Arriola et al, 2008). 
VAPB was also identified as a gene that was upregulated upon transition 
from a benign to malignant phenotype (Rizki et al, 2008). The acquisition of 
invasiveness is critical to the metastatic process. Breast cancer progression is a 
multi-step process beginning with localized, neoplastic growth, loss of polarity, 
increased motility, and ability to invade the surrounding extra-cellular matrix 
(Eckhardt et al, 2012). Microarray analysis on isogenic “pre-invasive” and 
“invasive” cell lines showed the upregulation of genes belonging to several 
functional groups including protein kinases, transcription factors, and intracellular 
vesicle transport, including elevated VAPB expression. 
Taken together these observations suggest that VAPB has an important 
role in breast cancer. To complement the published data and demonstrate 
VAPB’s clinical significance, we investigated VAPB expression in a published 
human breast cancer microarray dataset from a panel of 295 patient samples 
(van de Vijver et al, 2002). In collaboration with the Vanderbilt-Ingram Cancer 
Center Biostatistics Shared Resource, we categorized each patient’s gene 
expression values as “high” (top 25%) or “low” (bottom 25%) and found that high 
levels of VAPB significantly associated with worse recurrence-free survival than 
in patients with low VAPB expression, based on Kaplan-Meier survival analysis 
(Figure 1.2A). Similar results were also achieved using a second, independent 
dataset (Figure 1.2B). Complementary to this approach, we assessed VAPB 
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Figure 1.2. Analysis of VAPB expression in human breast cancer VAPB 
expression levels were analyzed in two published breast cancer microarray 
datasets. Correlation of VAPB expression with clinical outcome was analyzed by 
Kaplan-Meier survival curve using the (A) van de Vijver dataset (van de Vijver et 
al, 2002) and the (B) Wang dataset (Wang et al, 2005). (C) VAPB protein expres-
sion was analyzed in human invasive ductal carcinoma samples on commercial 
tissue microarrays by immunohistochemistry using a previously validated anti-
VAPB antibody, as described in Materials and Methods (Chapter II). (D) Western 
analysis of human and mouse tumor cell lysates. 
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protein expression in human breast cancer tissue microarrays (TMA). We 
observed a significant increase in the number of VAPB-positive invasive ductal 
carcinoma (IDC) and metastasis samples compared to normal tissue (Figure 
1.2C). Taken together, these data highlight the clinical relevance of VAPB in 
breast cancer and solicit more functional studies to understand VAPB’s role in 
breast tumor cell growth and invasion.  
 
Summary 
VAPB was originally defined as VAMP binding protein, also known as 
VAPs. Numerous studies implicate VAPs in a wide range of cellular processes, 
demonstrated in different species and cell types. VAPs function in, but are not 
limited to, neurotransmitter release, vesicle trafficking, lipid metabolism and 
transfer, the unfolded protein response (UPR), viral replication, and Eph receptor 
tyrosine kinase (RTK) signaling. 
VAPB is one of three mammalian homologues of VAPs. The other 
members include VAPA and VAPC (a VAPB splice variant) (Nishimura et al, 
1999). VAPA and VAPB share high sequence homology and primary 
organization, consisting of three conserved domains: an N-terminal major sperm 
domain (MSP), a coiled-coil (CC) domain and a C-terminal transmembrane 
domain (TM), with each domain mediating cytosolic protein interactions, 
dimerization, and ER localization, respectively. Within the MSP domain, a 
missense mutation (P56S) in human VAPB is associated with atypical 
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amyotrophic lateral sclerosis (ALS). This mutation disrupts the normal localization 
of VAPB, forming inclusion bodies with functional consequences on calcium 
homeostasis and NE and ER architecture.  
Not only are VAPB mutations detrimental to VAPB function, abnormal 
expression levels of VAPB are also critical to other human pathologies such as 
cancer. Result from other laboratories as well as our own, show VAPB as 
aberrantly expressed in human breast cancer. Combined analysis of genome 
copy number and gene expression analysis of 145 clinical specimens and 50 
human breast cancer cell lines revealed that VAPB, in addition to HER2, is one of 
66 genes overexpressed by genomic copy number abnormalities. Another study 
revealed recurrent amplification of VAPB in HER2-amplifed invasive breast 
cancer patient samples. Moreover, VAPB mRNA expression is also upregulated 
in a breast tumor cell model of pre-invasive to invasive transition, suggesting that 
VAPB enhances tumor cell invasion. Our own data corroborates with these 
studies. We show that high VAPB expression significantly correlates with poor 
clinical outcome and increased VAPB protein expression in human breast tumor 
samples. Despite VAPB’s clinical relevance and its role in diverse cellular 
processes, the precise function of VAPB in breast cancer is poorly understood. 
 
Thesis Project 
In our studies proposed herein, we demonstrate the causal role between 
VAPB and breast cancer, specifically in three areas (1) cell growth (2) invasion 
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and (3) tumor growth in vivo. Our results show that VAPB is important for breast 
tumor cell growth, affecting proliferation both in vitro and in mammary gland 
transplantation experiments. We also provide evidence that VAPB elevates the 
invasive potential of mammary epithelial cells. These phenotypes are, at least, 
partly mediated through enhanced AKT activation, a critical mitogenic signaling 
pathway in breast cancer. We have also identified novel proteins found in- 
complex with VAPB. The functional groups associated with VAPB-interacting 
proteins suggest that multiple pathways converge through VAPB to promote 
tumor proliferation and invasion. Additionally, we generated VAPB-deficient mice 
that overexpress the rat homologue of HER2 specifically in the mammary gland 
and scored spontaneously arising tumors for size and proliferation. Collectively, 
the genetic, functional and mechanistic analyses suggest an important function of 
VAPB in human breast cancer. 
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CHAPTER II 
 
VAMP-ASSOCIATED PROTEIN B (VAPB)  
PROMOTES BREAST TUMOR GROWTH BY  
MODULATION OF AKT ACTIVITY 
 
Introduction 
Vesicle associated membrane protein associated protein B (VAPB) is a 
highly conserved type II integral membrane protein that belongs to the VAP 
protein family (Nishimura et al, 1999; Weir et al, 1998) and primarily localizes to 
the endoplasmic reticulum (ER) and cis-Golgi (Moumen et al, 2011; Skehel et al, 
2000). Studies of VAP-interacting proteins in yeast and in higher organisms 
implicate VAP proteins in a diverse array of cellular processes. VAP proteins 
function in the regulation of neurotransmitter release, vesicle trafficking, lipid 
binding and transfer proteins, maintainance of ER/ golgi architecture and the 
unfolded protein response (UPR) (Gkogkas et al, 2008; Loewen et al, 2003; 
Skehel et al, 1995; Soussan et al, 1999). Recent studies in C. elegans and 
Drosophila discovered that the Major Sperm Protein (MSP) domain of VAPB can 
be cleaved, secreted, and act as a ligand for Eph receptor tyrosine kinases 
(Tsuda et al, 2008).  A single missense mutation within the human VAPB gene is 
associated in a familial form of atypical amyotrophic lateral sclerosis (ALS) 
(Kanekura et al, 2006; Nishimura et al, 2004; Suzuki et al, 2009), triggering a 
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renewed interest in the VAPB protein and its cellular function in human 
pathologies. 
In addition to familial ALS, VAPB expression has been observed in breast 
cancer.  A genome-wide microarray analysis of 50 human breast cancer cell lines 
and 145 clinical specimens revealed that VAPB is overexpressed in breast 
cancer. Similarly, identification of a VAPB-IKZF3 fusion protein and high VAPB 
genomic amplification in breast cancer cells (Kao et al, 2009) suggest that VAPB 
plays in important role in cancer cell growth. Furthermore, as VAPB also 
functions in protein secretion and vesicle trafficking, tumor cells may rely on this 
pathway for receptor localization and growth factor secretion in order to sustain 
growth (Hanahan & Weinberg, 2011). Despite strong indications of the 
consequences of VAPB expression in cancer, a direct role of VAPB in tumor 
growth has not been investigated. 
 In this report, we studied the role of VAPB in breast cancer.  We analyzed 
the expression of VAPB in breast cancer tissue microarray and publically 
available large breast cancer RNAmicroarray datasets, correlating VAPB 
expression with clinical outcomes.  To determine the causal role of VAPB in 
cancer, we overexpressed VAPB in mammary epithelial cells or stably knocked 
down VAPB in tumor cells.  Cell proliferation, apoptosis, spherical growth in 3D 
culture, and tumor growth in vivo were analyzed.  Finally, we identified molecular 
mechanisms by which VAPB regulates tumor cell proliferation. 
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Materials and Methods 
 
Antibodies and Reagents  
Antibodies against the following proteins were used: anti-VAPB (K-16), 
anti-actin (I-19), anti-β-tubulin (Santa Cruz Biotechnologies), and anti-PCNA 
(NeoMarkers), anti-Myc, anti-pThr308AKT, anti-pSer473AKT, anti-pERK, anti-
AKT, anti-ERK (Cell Signaling Technologies). Lentiviral control and VAPB shRNA 
plasmids KD# 1 (5ʹ′-GCACACACAAATATAGCATAA-3ʹ′) and KD# 2 (5ʹ′-
CGGAAGACCTTATGGATTCAA-3ʹ′) and VAPB cDNA were obtained from 
OpenBiosystems. Growth factor-reduced Matrigel and TO-PRO3 was purchased 
from BD Biosciences and Invitrogen, respectively. The AKT 1/2 inhibitor 
5J8/0360263-1 was produced by the Vanderbilt University Department of 
Chemistry as described previously (Lindsley et al, 2005).  Erlotinib was a 
generous gift from the laboratory of Dr. William Pao (Vanderbilt University). 
 
DNA constructs 
VAPB mutants PCR products were sub-cloned into the pCLXSN retroviral 
expression vector. VAPB-ΔMSP was constructed using the following forward and 
reverse primers: 5′ - CGGAATTCATGGAGAATGATAAACCACATGAT -3′, 5′-
CGGGATCCTCAATGGTGATGGTGATGATGACC-3′. The ΔCC mutant was 
constructed as previously described (Kim et al, 2010). The ΔCC (aa Δ159–196) 
mutant was constructed using three PCR steps. The first two PCR products 
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correspond to the 5′ and 3′ DNA sequences upstream and downstream of the 
CCD. Each of these PCR products consists of complementary sequences 
flanking the boundaries of the CCD. Annealing of these two PCR products and 
further amplification with primers corresponding to the 5′ and 3′ sequence of the 
full-length VAP-B results in the production of the ΔCC mutant. The following set 
of sense and antisense primers have been used: for 5′ amplification: 5′-
CCGGGATCCGCGAAGGTGGAGCA-3′; 5′-
CTGTCTTCCTCATCCGACTCAGAGACTTAGACAC-3′; for 3′ amplification: 5′-
GTGTCTAAGTCTCTGAGTCGGATGAGGAAGACAG-3′ and 5′-
CGGGATATCCTACAAGGCAATCTTCCCAAT-3′. For full-length amplification: 
5′-CCGGGATCCGCGAAGGTGGAGCA-3′ and 5′-
CGGGATATCCTACAAGGCAATCTTCCCAAT-3′. VAPB sMSP was constructed 
by flanking the amino acids (1-132) with EcoRI and BamHI. The resultant PCR 
product was sub-cloned into pCLXSN.  
 
Human mRNA expression profiling and tissue microarray protein analyses 
Analysis of VAPB mRNA expression in human breast cancer datasets 
(van de Vijver et al, 2002; Wang et al, 2005) was performed in collaboration with 
the Vanderbilt-Ingram Cancer Center's Biostatistics Core Resource. VAPB “high” 
or “low” expression was defined as top or bottom quartiles of tumors expressing 
VAPB.  Expression levels were analyzed in relation to overall and/or recurrence-
free survival using Log Rank and Cox analyses.  Statistical analyses were 
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performed using Software: R2.12.1. The survival curves from Kaplan-Meier was 
created and plotted by the function “survfit” under R package “survival.”  P values 
shown on KM plots were calculated based on log rank test between two survival 
curves of high or low expression groups. 
Breast tumor spectrum Tissue Microarrays (TMAs; BR480) were 
purchased from US Biomax, Inc. (Rockville, MD).  Immunohistochemical staining 
for VAPB was performed as described previously (Brantley et al, 2002; Brantley-
Sieders et al, 2008) using a previously validated rabbit anti-VAPB antibody 
(Amarilio et al, 2005).  Briefly, tumor sections were re-hydrated and subjected to 
thermal antigen retrieval in citrate buffer (2 mM citric acid, 10 mM sodium citrate, 
pH 6.0) using a PickCell Laboratories 2100 Retriever as per manufacturer’s 
instructions.  Endogenous peroxidases were quenched by incubation in 3% H2O2 
solution for 30 minutes.  After blocking, sections were incubated with anti-VAPB 
(1:25, produced in the Lev lab) overnight at 4˚C, followed by a biotinylated goat 
anti-rabbit secondary antibody (1:200, BD Pharmingen, San Diego, CA), an 
avidin-peroxidase reagent (Life Technologies/Molecular Probes, Carlsbad, CA), 
and stained with liquid 3,3’-diaminobenzidine tetrahydrochloride (DAB) substrate 
kit (Life Technologies/Zymed Laboratories). Relative expression in TMAs was 
scored using a continuous scale (Amarilio et al, 2005) as follows: 0 = 0-10% 
positive tumor epithelium, 1 = 10-25% positive tumor epithelium, 2 = 25-50% 
positive tumor epithelium, and 3 = >50% positive tumor epithelium/core.  
Differential expression between tissue samples was quantified and analyzed 
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statistically (Chi square analysis). 
 
Cell culture and generation of stable VAPB knockdown or overexpression cell 
populations 
MCF10A, MCF7, HBL100, BT-474, BT-549, T47D, SKBR3, MDA-MB-436, 
MDA-MB-468, MDA-MB-231 were obtained from American Type Culture 
Collection (ATCC) and grown in culture per ATCC protocol. MMTV-Neu tumor 
cells were isolated as previously described (Muraoka et al, 2003) and grown in 
DMEM/F-12 (Invitrogen) supplemented with 10% Fetal Bovine Serum (FBS) 
(Hyclone), 5ng/mL estrogen (Sigma-Aldrich), 5ng/mL progesterone (Sigma-
Aldrich), 5ng/mL EGF (PreproTech), 5µg/ mL insulin (Sigma-Aldrich) with 
penicillin/streptomycin. For generation of stable VAPB knockdown cells, Vector-
only (pLKO.1) or VAPB shRNA lentivirus was produced by co-transfecting HEK-
293T cells with pLKO.1 or pLKO.1-shRNAs, along with packaging plasmids 
psPAX2 and pMD.2G, using Lipofectamine. Viral supernatants were collected 48 
and 72 hours post transfection and used to infect MMTV-Neu tumor cells. MMTV-
Neu cells were selected for plasmid inclusion by culturing cells in growth media 
containing 5µg/mL of puromycin (Sigma-Aldrich). For re-expression of VAPB, 
VAPB cDNA (open reading frame) was subcloned into pCLSXN retroviral vector 
that contains a Neomycin resistance gene, allowing for G418 (300µg/mL for 6 
days) selection in puromycin-resistant populations. Viral supernatant was 
collected as described above from HEK 293T cells that were co-transfected with 
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pCLSXN-Vector (10µg) only or pCLSXN-VAPB (10µg) and pCLAmpho plasmids 
(10µg) using Lipofectamine 2000.  
MCF10A cells were obtained from American Type Culture Collection 
(ATCC) and cultured as previously described (Debnath et al, 2003). MCF10A-
HER2 cells were generated via retroviral transduction of the HER2 proto-
oncogene (Ueda et al, 2004).  Overexpression of VAPB in MCF10A-HER2 cells 
was achieved by infecting cells with pCLXSN-Vector or -VAPB retrovirus and 
selected in media containing 300µg/mL G418 for 6 days.  
 
Analysis of 3-dimensional spheroid culture 
 MMTV-Neu tumor cells or MCF10A-HER2 cells were plated on a solidified 
layer of Matrigel (2 mm thick) using an 8-well, glass chamber slide (Thermo 
Scientific) as previously described (Brantley-Sieders et al, 2008; Debnath et al, 
2003). Fresh MMTV-Neu growth media or MCF10A-HER2 Assay Media 
(Debnath et al, 2003) was replaced every 48 hours. Cultures were maintained for 
9 days prior to photo-documentation. Digital images were taken in 4 random 
fields/ well (3-4 spheroids/ field). Total spheroid area was calculated using NIH 
Image J software. For spheroid proliferation analysis, cultures were fixed at day 5 
in a 1:1 methanol: acetone solution for 10 minutes at -20°C and co-stained with 
anti-PCNA (1:1000) and nuclear stain TO-PRO3 (1:2000) as previously 
described (Debnath et al, 2003). Confocal images of 15 spheroids per 
experiment were taken at random and percentage of PCNA-positive nuclei was 
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quantified. For AKT inhibitor-treated spheroid cultures, cells were allowed to grow 
for 48 hours, followed by AKT-inhibitor or vehicle control treatment starting on 
day 3. Fresh media containing inhibitor or control was added every 48 hours. For 
each analysis described above, at least two to three independent experiments 
were performed. 
 
In vivo tumor studies 
 All animals were housed under pathogen-free conditions, and experiments 
were performed in accordance with AAALAC guidelines and with Vanderbilt 
University Institutional Animal Care and Use Committee approval. FVB female 
recipient animals (3-4 weeks of age) were cleared of endogenous epithelium as 
described previously (Brantley et al, 2001) and one million MMTV-Neu tumor 
cells were injected orthotopically. A total of 8-10 animals per group were 
analyzed in 2 independent experiments. Resulting tumors were harvested 4-5 
weeks after injection for analysis of tumor volume (volume = length x width2 x 
0.52). Harvested tumors were further processed for H&E staining and 
immunohistochemistry analysis of proliferation (Ki67) or apoptosis (cleaved 
caspase-3).  Proliferating tumor cells were quantified by enumerating Ki67 
positive nuclei in 4 random fields per tumor and presented as a percentage of 
Ki67+nuclei/total nuclei.  A total of 8-10 tumors were quantified in two 
independent experiments.  Statistical significance was assessed by single factor 
ANOVA. 
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Immunoblotting 
For immunoblot analysis of VAPB knockdown or overexpression, cells 
were washed with PBS and lysed in Radioimmunoprecipitation Assay (RIPA) 
buffer (50mM Tris pH 7.4, 150mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% 
SDS) supplemented with protease and phosphatase inhibitor tablets (Roche). 
Approximately 30-50ug of total cell lysate was separated by SDS-PAGE and 
probed with anti-VAPB (1:1000) overnight in 5% nonfat dry milk/ TBS-Tween 
(0.05%) and detected with anti-goat HRP (1:1000). For analysis of pAKT levels in 
VAPB expressing cells, cells were serum starved overnight and stimulated with 
DMEM/F-12 with 20ng/mL of EGF for the indicated time points or in the presence 
of erlotinib (1µM). For some experiments, an AKT inhibitor (0.1µM or 1µM ) was 
added under normal growth conditions for 3 hours prior to cell lysis. Data are a 
representation of three independent experiments. 
 
Statistical analysis 
Results are presented as mean values±standard error. P-values are given 
in the figure legends, and values of P < 0.05 were considered to be statistically 
significant. Statistical analyses were performed by single factor ANOVA and 
unpaired, two-tailed Student t-test using PRISM software (GraphPad Sofware, La 
Jolla, CA, USA). For TMAs, statistical significance of VAPB expression between 
patient samples was determined by Chi-Square analysis.  
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Results 
 
VAPB is overexpressed in breast cancer and negatively correlates with 
patient survival 
Several studies reported an increase in VAPB gene copy number or VAPB 
expression in breast cancer (Arriola et al, 2008; Chin et al, 2006; Edgren et al, 
2011; Kao et al, 2009; Neve et al, 2006; Rizki et al, 2008). To determine the 
impact of VAPB expression on clinical outcome in human breast cancer, we 
analyzed VAPB mRNA expression in a published human breast cancer 
microarray dataset from a panel of 295 patient samples (van de Vijver et al, 
2002). Kaplan-Meier analysis revealed that high levels of VAPB mRNA were 
significantly associated with poorer recurrence free survival (Figure 1.2A) than in 
patients with low VAPB mRNA expression. Similar results were obtained from a 
second, independent patient data set (n = 286) (Figure 1.2B) (Wang et al, 2005). 
To assess VAPB protein expression in human breast cancer, we performed 
immunohistochemistry in breast cancer tissue microarrays (TMA, n=84) with a 
previously validated anti-VAPB antibody (Amarilio et al, 2005).  As shown in 
Figure 1.2C, we observed a significant increase of VAPB expression in invasive 
ductal carcinoma and lymph node metastasis samples, compared to normal 
tissue (p < 0.01, Chi-square test). We also observed differential VAPB protein 
expression in breast tumor cell lines, with higher VAPB expression in HER2- 
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positive breast cancer cell lines (Figure 1.2D).  Taken together these data 
highlight the clinical relevance of high VAPB expression in human breast cancer.  
 
VAPB promotes tumor spheroid growth by enhancing tumor cell 
proliferation 
Because the VAPB is often overexpressed in human breast cancer 
(Arriola et al, 2008; Chin et al, 2006; Neve et al, 2006), we sought to determine if 
elevated VAPB expression enhances tumor cell growth.  MCF10A-HER2 cells, 
an immortalized mammary epithelial cell line with low level of endogenous VAPB, 
were transduced to express human VAPB protein (Figure 2.1A). Tumor spheroid 
growth was quantified in a three-dimensional culture. As previously reported, 
control MCF10A-HER2 cells formed large acinar-like structures with a filled 
lumen (Debnath et al, 2003). Expression of VAPB in MCF10A-HER2 cells led to 
larger, irregular structures with invasive protrusions and a significant increase of 
spheroid size relative to parental and vector controls (Figure 2.1B).  
 
To investigate which VAPB domains are critical for enhanced spheroid 
growth, we constructed several VAPB truncation mutants as illustrated in Figure 
2.9A. Upon stable expression of VAPB mutants in MCF10A-HER2 cells (Figure 
2.9B), we measured spheroid growth in 3-dimensional culture. Interestingly, all 
three mutants impaired spheroid growth as compared with WT VAPB (Figure 
2.10). Given that the MSP, CC and TM domains facilitate cytosolic protein 
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Figure 2.1. VAPB expression enhances spheroid size and proliferation in mam-
mary epithelial cells. (A) VAPB was stably expressed in MCF10A-HER2 cells via 
retroviral transduction, as judged by western blot analysis. (B) MCF10A-HER2-VAPB 
spheroids were cultured in three-dimensional Matrigel. Spheroid size was quantified 
and presented as average pixel area per spheroid (p < 0.01, ANOVA). (C) Cell 
proliferation in spheroid culture was determined by immunofluorescence using an 
anti-PCNA antibody (red). Cell nuclei were stained blue by TO-PRO-3 nuclear stain. 
PCNA-positive nuclei were quantified from an average of 15 random spheroids for 
each of two experiments (p<0.05, t test). Arrows: PCNA positive cells.  
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interactions, VAPB self-dimerization, and VAPB localization to the ER 
respectively, this suggests that these functions are important for VAPB-mediated 
spheroid growth.  
 
To determine whether increased tumor spheroid size is due to increased 
cell proliferation, the tumor spheroids were stained for proliferating cell nuclear 
antigen (PCNA), a cell proliferation marker. As shown in Figure 2.1C, VAPB 
expression elevated the number of PCNA-positive nuclei per spheroid, 
suggesting that VAPB regulates cell proliferation. Apoptosis, as measured by 
cleaved caspase 3 staining of 3D spheroid cultures, was not significantly 
changed (Figure 2.5A).  
 
As an independent approach to determine whether VAPB is necessary for 
tumor cell growth, we knocked down VAPB in MMTV-Neu cells. These cells are 
derived from spontaneously arising mammary tumors from the MMTV-Neu 
mouse model (Muraoka et al, 2003). Stable expression of two independent 
shRNAs significantly reduced VAPB protein levels (Fig. 2.2A) but not the related 
protein VAPA (Figure 2.2C), suggesting that shRNAs specifically downregulated 
VAPB expression.  In contrast to the morphology of vector control spheroids, 
which displayed disorganized and irregular structures with protrusions, 
knockdown of VAPB resulted in much smaller and more compact tumor 
spheroids (Figure 2.3A). Since one of the VAPB shRNA sequences (KD #1) 
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Figure 2.2. Specificity of VAPB shRNA knockdown. (A) VAPB expression 
was silenced in MMTV-Neu tumor cells by two independent lentiviral-
mediated shRNAs, as judged by western blot analysis.  (B) VAPB knockdown 
(KD #1) cells were rescued by re-expressing a full-length human VAPB cDNA 
via retroviral transduction. (C) VAPA protein expression was not affected by 
VAPB shRNA, as judged by western blot analysis.
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Figure 2.3. VAPB knockdown impairs mammary tumor spheroid growth 
and cell proliferation. (A) MMTV-Neu spheroids were cultured in three-
dimensional Matrigel. Spheroid size was quantified and presented as average 
pixel area per spheroid (p < 0.01, ANOVA). (B) MMTV-Neu cell proliferation in 
spheroid culture was determined by immunofluorescence using an anti-PCNA 
antibody (red). PCNA-positive nuclei were quantified from an average of 15 
random spheroids for each of two experiments (p<0.05, t test). Arrows: PCNA 
positive cells.
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targeted the 3ʹ′ UTR, we were able to re-express full-length human VAPB protein 
(Figure 2.2B). Re-expression of VAPB restored tumor spheroid size and irregular 
morphology, demonstrating that phenotypes induced by shRNAs are VAPB 
specific and not due to off-target effects (Figure 2.3A). Knockdown of VAPB 
significantly reduced proliferation in spheroid cultures as quantified by PCNA 
staining (Figure 2.3B), without affecting apoptosis as measured by cleaved 
caspase 3 staining of 3D spheroid cultures (Figure 2.5B). Together, these data 
indicate that VAPB regulates tumor spheroid size by increased tumor cell 
proliferation.  
 
VAPB promotes tumor growth in an orthotopic mammary tumor model 
Next, we investigated the role of VAPB in tumor growth in vivo in a 
mammary tumor orthotopic transplantation model (Brantley-Sieders et al, 2008). 
One million MMTV-Neu control or VAPB knockdown cells were injected into 
cleared mammary gland fat pads of FVB recipient female mice. VAPB 
knockdown tumor cells failed to form tumors or formed very small, non-palpable 
tumors at five weeks post-transplantation, compared to parental or vector 
controls (Figure 2.4A). While parental or vector control tumors display densely 
packed tumor cells, VAPB knockdown tumors exhibit a reduced mammary tumor 
cell content (Figure 2.4B). To examine changes within the tumor epithelium, we 
assessed tumor proliferation and apoptosis in tissue sections by staining for Ki67 
and cleaved caspase-3, respectively. We observed a significant decrease in 
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Figure 2.4. VAPB is required for tumor growth in vivo. (A) One million of 
MMTV-Neu control or VAPB knockdown cells were injected into cleared mam-
mary gland fat pads of 3-week old FVB recipient female mice (n=8-
10/experimental condition).  Tumors were harvested 5 weeks after transplanta-
tion.  Tumor size was measured by a caliper and tumor volumes were calcu-
lated. (p < 0.05, ANOVA). (B) Tumors were processed, sectioned and stained 
with H&E (B) or Ki67, a proliferation marker (C). Proliferating tumor cells were 
quantified by enumeration of Ki67+ nuclei and presented as a percentage of 
Ki67+ nuclei/total nuclei. VAPB knockdown cells showed a significant decrease 
in proliferation (p < 0.05, ANOVA). Arrows: Ki67 positive cells.  
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Figure 2.5. VAPB expression does not affect apoptosis. (A) MCF10A-HER2 
or (B) MMTV-Neu knockdown cells were stained for cleaved caspase-3 at day 8 
in 3-dimensional culture. Cleaved caspase-3 positive spheroids (green) were 
quantified by confocal microscopy analysis. No significant changes were 
observed in both cell lines. (C) in vivo analysis of apoptosis was measured by 
cleaved caspase-3 staining of tumor sections. Cleaved caspase -3 positive 
nuclei were quantified. VAPB deficiency does not significantly affect apoptosis in 
vivo. Arrows: cleaved caspase-3 positive cells. 
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tumor cells with Ki67 nuclear staining (Figure 2.4 C). Whereas cleaved caspase-
3 levels were unaffected (Figure 2.5C). These data suggest that loss of VAPB 
inhibits HER2-initiated mammary tumor proliferation in vivo. 
 
VAPB-induced cell proliferation is mediated by elevated AKT activity 
 To understand the mechanisms through which VAPB enhances 
proliferation, we investigated potential links between VAPB and signaling 
molecules relevant to tumor growth.  Because ERK and AKT signaling pathways 
are two major players in regulating cell proliferation in mammary tumor cells, we 
assessed their activities by western blot analysis.  MCF10A-HER2 or VAPB 
knockdown MMTV-Neu cells carrying either wild-type VAPB expression construct 
or the control vector were serum-starved overnight and stimulated with EGF at 
the indicated time points. In response to EGF stimulation, there is a rapid 
increase in phosphorylation of AKT at both Thr308 and Ser473 residues, 
indicating activation of its kinase activity. The phospho-AKT levels were 
significantly increased in MCF10A-HER2 cells overexpressing VAPB than those 
carrying the control vector (Figure 2.6A). Re-expression of VAPB in knockdown 
cells restored AKT phosphorylation to control levels (Figure 2.6B). In contrast, 
ERK phosphorylation levels were not changed between two cell populations 
(Figure 2.6). These results indicate that AKT may play a key role in regulating cell 
growth in these cells.  
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Figure 2.6. Analysis of AKT and ERK activities in VAPB expressing cells. 
(A) MCF10A cells expressing VAPB or carrying control vector were serum 
starved and stimulated with 20ng/mL EGF at the indicated time points. As a 
negative control for EGF stimulation, cells were treated for 60 minutes with 
EGFR inhibitor, erlotinib (1μM). Phospho-AKT and phospho-ERK levels in 
MCF10A-HER2 cells were measured by western blot analysis and quantified. 
Representative blots from 3 independent experiments are shown. (B) VAPB was 
knocked down in MMTV-Neu cells and re-expressed via retroviral transduction. 
Cells were stimulated as in (A) and phospho-AKT and phospho-ERK levels 
were measured by western blot analysis and quantified.  Representative blots 
from 3 independent experiments are shown. 
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Figure 2.7. VAPB-dependent cell growth is mediated through AKT activity. 
Pharmacologic AKT inhibition significantly impaired VAPB-mediated spheroid 
growth in (A) MCF10A-HER2 cells  and (C) MMTV-Neu VAPB knockdown cells 
rescued with VAPB re-expression (p < 0.05). Inhibition of AKT activity was 
confirmed by western blot analysis for phospho-AKT in (B) MCF10A-HER2 
cells and (D) MMTV-Neu knockdown cells. 
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Figure 2.8. PI3K inhibition attenuates VAPB dependent spheroid growth. 
(A) Cells were cultured in 3D Matrigel for 2 days and then treated with 
LY294002 (20μM) or vehicle control every 2 days. Tumor cell spheroids were 
quantified at day 8. (B) Inhibition of AKT activity was confirmed by western blot 
analysis for phospho-AKT levels. Shown were representative blots from two 
independent experiments.
          47
AFigure 2.9. VAPB mutant panel. (A) Schematic of human VAPB wildtype or 
mutant tagged with Myc/ 6x His. Sequences were inserted into pcLSXN_Neo 
retroviral vector. (B) MMTV-Neu VAPB knockdown tumor cells or MCF10A-
HER2 cells were infected and cell lysates were subjected to western analysis to 
confirm protein expression.  
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Figure 2.10. Mutant VAPB expression impairs spheroid growth. MCF10A-
HER2 cells expressing WT or mutant VAPB were grown in 3D culture. The size 
was quantified at day nine. Expression of mutant VAPB significantly impaired 
spheroid size when compared with WT VAPB (p < 0.05 Single Factor ANOVA).
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To test if VAPB-mediated spheroid growth is dependent on AKT 
phosphorylation, cells were treated with an allosteric AKT inhibitor (Lindsley et al, 
2005). AKT inhibition significantly reduced spheroid growth of VAPB expressing 
cells (Figure 2.7A and 2.7C). As expected the AKT inhibitor reduced 
phosphorylated AKT, while phospho-ERK was unaffected (Figure 2.7 B and 2.7 
D). Similar results were obtained using the LY294002, a PI3K inhibitor (Figure 
2.8) in MCF10A-HER2 cells. Although these results do not rule out the 
contribution of other signaling pathways, our findings suggest that VAPB-induced 
proliferation is mediated, at least in part, through activation of the AKT pathway. 
 
Discussion 
VAPB was originally identified as one of the vesicle-associated membrane 
protein (VAMP) associated proteins.  Although VAPB was implicated in a wide 
range of cellular processes, its function in cancer has not been characterized.  In 
this report, we provide evidence that VAPB regulates mammary tumor growth 
and proliferation via activation of AKT activity.  VAPB protein expression is 
elevated in primary and metastatic tumor specimens, and VAPB mRNA 
expression levels correlated negatively with patient survival in two large breast 
tumor datasets. Overexpression of VAPB increased spheroid size and 
proliferation in MCF10A-HER2 cells.  Conversely, knockdown of VAPB in MMTV-
Neu mammary tumor cells inhibited tumor cell proliferation in 3-D culture in vitro 
and suppressed tumor growth in orthotopic mammary tumor allografts.  The 
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growth regulation of mammary tumor cells controlled by VAPB appears to be 
mediated, at least in part, by modulation of AKT activities. Collectively, the 
genetic, functional and mechanistic analyses suggest a role of VAPB in tumor 
promotion in human breast cancer. 
Approximately 30% of all breast tumors have mutations in one or more 
components of the PI3K/AKT pathway (Stemke-Hale et al, 2008). Two lines of 
evidence suggest that VAPB expression modulates AKT activation. First, 
overexpression of VAPB in MCF10A-HER2 cells enhanced phosphorylation of 
AKT, whereas knockdown of VAPB in MMTV-Neu tumor cells inhibited pAKT 
levels. Furthermore, the addition of an allosteric AKT inhibitor significantly 
reduced 3D spheroid growth induced by VAPB.  It is currently unclear how VAPB 
regulates PI3K/AKT activity.  Since VAPB does not contain known enzymatic 
activities, it is likely that its action is mediated by its interaction with other 
proteins. 
Major subcellular compartments where VAPB is localized are the ER and 
Golgi, where secretory and membrane proteins are synthesized and transported 
to the cell surface (Moumen et al, 2011; Skehel et al, 2000). Several studies 
show that VAPB is required for neurotransmitter release and functions in early 
secretory transport events (Skehel et al, 1995; Soussan et al, 1999). Therefore it 
is possible that VAPB may regulate the protein secretion. Indeed, when VAPB is 
overexpressed in MCF10A-HER2 cells, transport of VSV-G-GFP ts045, a protein 
used to monitor vesicle traffic from ER/Golgi to the plasma membrane, is 
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markedly enhanced (Figure 4.3), consistent with a previous report that show 
VAPB deficiency inhibited VSV-G-GFP ts045 to the plasma membrane in HeLa 
cells (Peretti et al, 2008). Accordingly, one mechanism by which VAPB promotes 
tumor cell proliferation could be through secretion of growth factors, cytokines, 
matrix metalloproteinases, as well as delivery of receptors to the cell surface 
(Hanahan & Weinberg, 2011).  This possibility is further strengthened by the fact 
that VAPB physically interacts with Arf1 (Figure 4.4A) and Rab1 (Figure 4.6), two 
small GTPases that are known to play critical roles in regulation of vesicle 
trafficking in the secretary pathway (D'Souza-Schorey & Chavrier, 2006; 
Gillingham & Munro, 2007; Plutner et al, 1991; Spang, 2002; Stenmark, 2009).  
Interestingly, Arf1 has also been implicated in recruitment of p85 subunits of 
PI3K to EGFR in breast cancer cells (Boulay et al, 2008), providing an additional 
possible mechanism by which VAPB could regulate AKT activities.  
Aside from interacting with Arf1/Rab1, we and others also found VAPB in 
complex with other proteins including lipid transfer binding proteins such as Nir2 
(Table 3) (Amarilio et al, 2005; Peretti et al, 2008), a phosphoinositol/ 
phosphotidyalcholine transfer protein. Deletion of scs2, the yeast homolog of 
VAPs, was reported to reduce phosphoinosotide levels (Kagiwada & Zen, 2003). 
Since AKT phosphorylation is dependent on recruitment to the plasma 
membrane through interaction between the PH domain and PIP3, such 
alterations in phosphoinositols at the plasma membrane could affect ultimately 
the activation of AKT. Given the diverse function of VAPB-interacting proteins 
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(Table 3), it is likely that multiple pathways converge through VAPB to enhance 
the AKT pathway and affect tumor cell proliferation. 
Our results suggest that VAPB enhances breast tumor cell proliferation is 
mediated through the AKT pathway. However we cannot rule out other functions 
of VAPB that also may contribute to the phenotypes observed in this study, such 
as lipid sensing and transport (Jansen et al, 2011; Kawano et al, 2006; Loewen & 
Levine, 2005) ER and Golgi architecture (Amarilio et al, 2005; Peretti et al, 2008), 
and the unfolded protein response (Gkogkas et al, 2008; Kanekura et al, 2006). 
Therefore further studies are needed to address whether perturbation in these 
mechanisms alters the phenotypes of tumor cells in relation to VAPB expression. 
Furthermore, although full-length VAPB localizes to the ER, Golgi, and 
membrane-bound vesicles (Lapierre et al, 1999; Moumen et al, 2011), a number 
of studies showed that the MSP domain of VAPB can be secreted and act as an 
antagonist for Eph receptor tyrosine kinases in C. elegans and Drosophila (Miller 
et al, 2003; Tsuda et al, 2008).  Secreted MSP has also been detected in human 
serum (Tsuda et al, 2008).  Because ligand-dependent EphA2 receptor signaling 
has been associated with tumor suppression whereas EphA2 ligand-independent 
signaling promotes tumor initiation and malignancy in breast cancer (Chen et al, 
2008; Vaught et al, 2008), it is tempting to speculate that the secreted MSP 
domain may compete with ligand for binding to EphA2 receptor, thereby blocking 
EphA2-tumor suppressive function as hypothesized in Figure 6.1B.  However, 
although tumor cells do secrete MSP (Figure 6.1A), thus far we are unable to 
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detect any biological activities of soluble MSP, using either conditioned media or 
purified recombinant soluble MSP proteins. Further investigations are required to 
test this hypothesis. 
In summary, we identified a functional role of VAPB in promoting tumor 
cell proliferation in breast cancer. While the expression of VAPB in other cancers 
has not been systematically investigated, this discovery opens up a number of 
exciting avenues for future studies of both full length VAPB and the secreted 
MSP domain.  As VAPB overexpression is associated with poor patient survival, 
targeting VAPB-associated protein secretory pathway may provide novel targets 
for future pharmacological strategies in breast cancer therapy. 
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CHAPTER III 
 
VAMP-ASSCOCIATED PROTEIN B (VAPB)  
ELEVATES THE INVASIVE POTENTIAL OF  
MCF10A-HER2 CELLS 
 
Introduction 
Metastasis is the major cause of death in breast cancer patients 
(Amercian-Cancer-Society, 2012). The metastatic cascade begins with tumor 
cells becoming increasingly mobile and breaking through the basement 
membrane to invade surrounding tissues. Eventually the disseminated tumor 
cells enter the blood stream (or lymphatics) and migrate to distant organs, 
leading to advanced stage breast cancer. Therefore, it is critical to understand 
the molecular alterations that contribute to tumor cell invasiveness, a critical step 
in the metastatic process (Chambers et al, 2002).  
Recently, Rizki et al., found elevated VAPB expression from microarray 
analysis on “pre-invasive” versus “invasive” cell lines derived from sub-culturing 
basal-like HMT-3522 cells in a 3-dimensional environment that mimics the 
extracellular matrix (ECM) (Rizki et al, 2008). Additional evidence to implicate 
VAPB in tumor cell invasion includes recurrent genomic amplification of VAPB in 
HER2 amplified invasive breast cancers (Arriola et al, 2008). Furthermore, our 
own data shows that VAPB protein is elevated in metastatic breast tumor 
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samples over control tissue (Figure 1.2C). These observations suggest that 
VAPB may promote invasiveness in breast cancer cells, thus contributing to 
increased malignancy and poor outcome associated with aberrant expression 
(Figure 1.2). 
Normal mammary glands contain highly polarized luminal epithelial cells, 
surrounded by a layer of basal epithelial cells in addition to various stromal cell 
types (Watson & Khaled, 2008). MCF10A cells are a valuable in vitro tool for 
modeling breast cancer genes and pathways in the context of invasion (Debnath 
et al, 2003; Lee et al, 2007). In three-dimensional cell culture, MCF10A cells 
mimic the highly organized acini-like structures found in mammary glands in vivo. 
Moreover, MCF10A cells secrete laminin V protein, a major component of the 
basement membrane (Debnath et al, 2003). The basement membrane 
encapsulates the assembled mammary epithelial structure, and plays an 
important role in maintaining cell polarity and serves as a barrier, preventing 
tumor cells from invading the surrounding tissue (Slade et al, 1999).   
Here we demonstrate that VAPB expression enhances the invasive 
behavior of MCF10A cells that express HER2. We found that VAPB expression 
led to abnormal acini morphology and laminin V localization in three-dimensional 
culture, suggesting a loss of basement membrane integrity. Furthermore, our 
data also show that VAPB increases growth factor-induced invasion, but not 
migration suggesting that VAPB promotes the early dissemination of cells.   
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Materials and Methods 
 
Antibodies and Reagents 
Antibodies against the following proteins were used: anti-VAPB (K-16), 
anti-E-cadherin (BD Biosciences), and anti-laminin5γ2 (Santa Cruz 
Biotechnologies). Growth factor-reduced Matrigel and TO-PRO3 was purchased 
from BD Biosciences and Invitrogen, respectively. 
 
Transwell assays 
Transwell filters (8 μm pore) (Corning Incorporated) were blocked with 1% 
BSA (Sigma) for 30 min at 37°C. Blocking solution was removed and filters were 
coated with a 1:20 dilution of Matrigel (BD Biosciences) in DMEM/F-12 plus 
Penicillin/ streptomycin (Invitrogen) for 2 hours at 37°C.  100,000 MCF10A-HER2 
control or VAPB expressing cells were seeded (200μL volume) on the top of the 
coated (invasion assay) or uncoated (migration assay) transwell filter in serum-
free and EGF-free DMEM/F-12. Immediately, the transwells were placed in 24-
well plates containing DMEM/F-12 media with or without EGF (20ng/mL) and 
were incubated at 37°C for 24 hours. For inhibitor studies, AKT 1/2 inhibitor 
5J8/0360263-1 (Vanderbilt University Department of Chemistry) was added to 
the bottom chamber at the indicated concentrations. Filters were fixed in 10% 
NBF and stained with crystal violet. Cells on the lower surface were counted in 
three random fields from each well, with duplicate samples per condition. 
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Cell culture and analysis of VAPB acini morphology 
MCF10A-HER2 cells were plated on a solidified layer of Matrigel (2 mm 
thick) using an 8-well, glass chamber slide (Thermo Scientific) as previously 
described (Brantley-Sieders et al, 2008; Debnath et al, 2003). Fresh MCF10A-
HER2 Assay Media (Debnath et al, 2003) was replaced every 48 hours. Cultures 
were maintained for nine days prior to photo-documentation. Quantification of 
invasive protrusions was performed as previously described (Chatterjee et al, 
2012) such that acini with one or more invasive protrusion was counted as 
“positive”. For spheroid morphology analysis, cultures were fixed at day nine in a 
1:1 methanol: acetone solution for 10 minutes at -20°C and co-stained with anti-
E-cadherin (1:1000), anti-laminin5γ2 (1:500) and TO-PRO3 nuclear stain 
(1:2000) as previously described (Debnath et al, 2003). For laminin V 
quantification, MCF10A-HER2 cells were stained with anti-laminin5γ2 at day five 
and nine. Confocal images of 30 randomly selected spheroids per experiment 
were taken and percentage of laminin staining surrounding each spheroid was 
quantified by NIH Image J software. 
 
VAPB immunofluorescence analysis 
MMTV-Neu or MCF10A-HER2 cells were plated on glass slides and 
incubated in growth media in a 6-well dish overnight. At 40 – 50 % confluence, 
the cells were fixed in 10% NBF for 15 minutes at room temperature. Slides were 
rinsed three times in PBS for 5 minutes each, then blocked in PBS/5% goat 
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rinsed three times in PBS for 5 minutes each, then blocked in PBS/5% goat 
serum for 1 hour at room temperature. Anti-VAPB was diluted 1:1000 in PBS 
containing 1% BSA/ 0.3% Triton-X (Sigma) overnight at 4°C. After washing, 
AlexaFluor (Invitrogen) secondary antibody (1:2000) was incubated for 4 hours at 
room temperature followed with TO-PRO-3 nuclear stain. Slides were mounted 
and analyzed by confocal microscopy. For “scratch” assays, MMTV-Neu tumor 
cells were cultured to confluence. After overnight serum starvation, cells were 
scratched with 200μL micro-pipet tip and normal growth media was replaced. 
Following a 24-hour incubation, cells were stained as described above.  
 
Results 
 
VAPB alters the morphology of MCF10A-HER2 acini. 
 While we demonstrated that ectopic expression of VAPB in MCF10A-
HER2 cells increased acini growth in 3-dimensional culture (Figure 2.1B), we 
also observed gross morphological changes in VAPB-expressing acini. 
Consistent with previous reports, parental and vector control MCF10A-HER2 
cells formed non-invasive acini structures (Figure 3.1A) and intact basement 
membrane structures as seen with laminin V immunofluorescence staining 
(Figure 3.1B) (Lu et al, 2009; Muthuswamy et al, 2001). However with the 
expression of VAPB, we observed an increase in invasive growth into the 
surrounding matrix as quantified in Figure 3.1A. Further analysis of the VAPB-
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Figure 3.1. VAPB induces invasive-like growth into the extracellular 
matrix. (A) MCF10A-HER2-VAPB cells were cultured in Matrigel. At day 9, 
cultures were photodocumented and scored for invasive growth (black arrows) 
as previously described (Chatterjee et al, 2012). Percentage of acini displaying 
invasive protrusions were quantified from three independent experiments (p < 
0.05, t-test) (B) Acini were stained at day 9 for TO-PRO-3 nuclear stain (blue), 
E-cadherin (red) and laminin Vγ2 (green) and imaged by confocal microscopy. 
Confocal analysis revealed MCF10A-HER2 VAPB acini displayed normal 
E-cadherin localization at the cell junction, but diminished laminin V localization 
at areas of invasive growth (white arrow).
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mediated invasive acini growth with confocal microscopy revealed a strong 
presence of E-cadherin at cell junctions but weak laminin V staining at the area of 
invasive growth into the matrix (white arrow) (Figure 3.1B).  
To address the observations seen in Figure 3.1B, we examined the effects 
of VAPB expression on basement membrane integrity by monitoring laminin V 
deposition. MCF10A cells normally deposit laminin V at the basal surface of acini 
by day five (Debnath et al, 2003), creating a continuous ring that surrounds each 
structure. Upon ectopic expression of VAPB in MCF10A-HER2 cells we observed 
a significant decrease in laminin V circumscribing each acini as analyzed by 
confocal microscopy at day nine. At day 5, both vector and VAPB-expressing 
cells have a continuous laminin V layer surrounding the acini, suggesting that 
laminin V is sufficiently produced in early stages of acinar growth. The results at 
day five and nine are quantified in the lower panel. These data support the idea 
that VAPB is an important factor that promotes the irregularity and invasive 
behavior of HER2-driven acini growth.  
 
VAPB expression elevates the invasive potential of MCF10A-HER2 cells 
 A critical step in the metastatic cascade is the acquisition of invasive 
characteristics such as increased tumor cell motility and the ability to break down 
ECM components (Hanahan & Weinberg, 2011). Therefore, we tested whether 
VAPB allowed for these characteristics in MCF10A-HER2 cells, using Transwell 
(Boyden chamber) assays. As seen in Figure 3.3A, VAPB expression 
          61
VAPBVector
Da
y 5
Da
y 9
0
20
40
60
80
100
Day 5 Day 9
Vector
VAPB
Pe
rc
en
t L
am
ini
n 
5 
St
ain
ing
 o
f
To
ta
l S
ph
er
oid
 P
er
im
et
er
 p <0.05
A
B
Figure 3.2. VAPB expression disrupts basement membrane integrity. (A) 
MCF10A-HER2 cells were cultured in Matrigel and stained at day five and 
day nine for lamininVγ2 (green) and TO-PRO-3 nuclear stain (blue) and 
analyzed by confocal microscopy. At day five both vector and VAPB express-
ing cells displayed continuous laminin V staining around each spheroid which 
was significantly reduced by day nine in VAPB-expressing cells only. (B) 
Quantification of 30 randomly selected spheroids from two independent 
experiments is shown in the lower panel (p < 0.05 ANOVA). 
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Figure 3.3. VAPB elevates the invasive potential of MCF10A-HER2 cells. (A) 
VAPB significantly increased  EGF-induced (20ng/mL) invasion through 
Matrigel-coated, Boyden chambers (Transwells).  (B) EGF- induced migration 
was assayed using uncoated Transwell filters. No significant difference was 
observed between vector and VAPB-expressing cells. (C) Pharmacologic inhibi-
tion of AKT significantly impaired EGF-induced invasion in VAPB expressing 
cells. Inhibition of AKT activity was confirmed by western blot analysis as shown 
in Figure 2.7 B. All results were quantified from three independent experiments 
(p < 0.05 ANOVA).
          63
Av
er
ag
e 
Nu
m
be
r o
f M
igr
at
ing
Ce
lls
/ 1
0x
 F
iel
d
Control EGF
Pa
re
nt
al
Ve
cto
r
VA
PB
0
100
200
300
400
500
600
Parental
Vector
VAPB
N.S
p < 0.05
Control EGF
0
100
200
300
Vector VAPB
Av
er
ag
e 
Nu
m
be
r o
f M
igr
at
ing
Ce
lls
/ 1
0x
 F
iel
d
p < 0.05
 Matrigel +
A
B
N.S
EGF
Ve
cto
r
VA
PB
 Matrigel
(Invasion)
 Uncoated
(Migration)
0
60
120
180
Control
AKTi (μM)  0.1 10 0 0.1 10 0
EGF
p < 0.05
Av
er
ag
e 
Nu
m
be
r o
f M
igr
at
ing
Ce
lls
/ 1
0x
 F
iel
d
Vector
VAPB
C
          64
significantly increased MCF10A-HER2 invasion through the Matrigel-coated 
Transwell filters in response to EGF (Figure 3.3A), demonstrating that VAPB 
imparts to MCF10A-HER2 cells the ability to breakdown the Matrigel layer, prior 
to migration through the membrane pores. However the results presented in 
Figure 3.3B suggest that VAPB does not affect cell motility because the 
differences seen between vector and VAPB-expressing are diminished when 
using uncoated Transwell filters, which tests for directional cell migration. Thus, it 
is likely that VAPB enhances the invasive capabilities of MCF10A-HER2 cells at 
the level of ECM breakdown, rather than increasing cell motility.  
Based on our earlier studies, we found that VAPB expression increases 
tumor cell proliferation through enhanced AKT activation (Chapter II). In addition 
to proliferation, invasion is also a process modulated by the AKT pathway (Chin 
& Toker, 2009). Therefore, we used the same allosteric AKT inhibitor as in Figure 
2.7, to test whether VAPB-induced invasion is dependent on AKT. Indeed, we 
find that pharmacologic inhibition of AKT significantly reduced invasion in VAPB-
expressing cells (Figure 3.4C). 
 
VAPB localization at the leading edge of cells 
Although VAPB primarily localizes to the ER, there is data to support that 
VAPs also localize to other intracellular membranes such as recycling 
endosomes, tight junctions and plasma membrane [Reviewed in (Lev et al, 
2008)]. Along these lines of data we also observed VAPB localization at the 
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leading edge of cells (Figure 3.5). Our data shows a distinct pattern of VAPB in 
both randomly migrating cells (Figure 3.5A and B) and in directional migration in 
MMTV-Neu tumor cells (Figure 3.5C) by immunofluorescence analysis. This 
VAPB staining pattern suggests the possibility of distinct interplay between VAPB 
and proteins that mediate cell motility or invasion at the plasma membrane. 
 
Discussion 
 The acquisition of invasiveness is a critical step during breast cancer 
metastasis. Our data demonstrate that VAPB expression elevates the invasive 
potential of HER2-expressing tumor cells. First, we found that VAPB increases 
the formation invasive protrusions in MCF10A cells engineered to express HER2. 
Upon closer examination of invasive growth by confocal microscopy, we 
observed normal E-cadherin localization at cell junctions, however, the laminin V 
staining was markedly diminished. Next, we found that VAPB-expressing cells 
had significantly reduced laminin accumulation around each acinus, signaling a 
loss of basement membrane integrity. These observations are in agreement with 
the data from our Transwell assays, showing that VAPB significantly increases 
invasiveness in MCF10A-HER2 cells and is, at least in-part, mediated through 
AKT signaling. 
Interestingly we observe no significant difference in EGF-induced cell 
migration between vector and VAPB-expressing cells, suggesting that VAPB has 
little effect on cell motility. While it is tempting to speculate that VAPB increases 
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Figure 3.4. VAPB localizes to the leading edge of cells.  Immunofluores-
cence analysis of VAPB protein revealed a distinct staining pattern at the leading 
edge of randomly migrating (A) MCF10A-HER2 VAPB cells and (B) MMTV-Neu 
tumor cells (white arrows). (C) MMTV-Neu tumor cells were subjected to a 
“scratch” assay to ensure directional migration of cells. A similar VAPB staining 
pattern was observed (white arrows). 
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invasive potential by inducing epithelial-to-mesenchymal transition (EMT), a 
process by which polarized cells gain motility, characterized by loss of E-
cadherin expression (Thiery, 2002), our data show clear junction staining of E-
cadherin with or without VAPB expression. This suggests that downregulation of 
E-cadherin may not be the primary mechanism promoting invasion in the context 
of VAPB. However, a more thorough analysis of EMT markers such as Vimentin, 
Snail and Twist is needed (Thiery, 2002).  
Rather than enhanced cell motility as a primary factor in VAPB-induced 
invasion, another potential mechanism that warrants further investigation is the 
role of matrix metalloproteinases (MMPs). MMPs are a family of proteins that 
remodel the ECM through proteolytic degradation its components, including 
collagens and laminin. MCF10A-HER2 cells secrete specific MMPs such as 
MMP-2 and MMP-9 that break down ECM components and facilitate invasion 
(McCawley & Matrisian, 2000). Interestingly it has been shown that AKT 
activation can increase the expression and activity of both MMP-2 and MMP-9, 
leading to enhanced invasive capabilities (Jin et al, 2007; Kim et al, 2009; 
Kwiatkowska et al, 2011). Therefore, future studies are needed to explore the 
possibility that the invasive phenotypes observed with VAPB expression are 
dependent on MMPs.  
 While the potential involvement of MMPs suggests that VAPB promotes 
the breakdown the basement membrane, it is equally likely that laminin V is being 
mis-localized. This alternative hypothesis is supported by the fact that there are 
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centrally-located cells with cytoplasmic localization of laminin V in VAPB-
expressing structures (Figure 3.1B and 3.2A). This is also consistent with the fact 
that VAPB has reported functions in vesicle trafficking [Reviewed in (Lev et al, 
2008)]. 
Many reports suggest that other players work in conjunction with HER2 to 
promote invasion like TGFβ (Chow et al, 2011; Seton-Rogers & Brugge, 2004), 
14-3-3ζ (Lu et al, 2009), EphA2 (Brantley-Sieders et al, 2008) and Integrin β4 
(Guo et al, 2006). While the status of these proteins is unknown in VAPB-
expressing cells, our observations that VAPB localizes at the leading edge 
suggests a sub-cellular localization where VAPB can foster interactions with the 
above-mentioned proteins. These data sparks interesting questions for future 
studies: (1) Which proteins does VAPB interact with at the leading edge of cells? 
(2) How do these interactions relate to the invasive potential of tumor cells?  
The data presented here also highlight several areas of interest in clinical 
breast cancer. An important feature of non-invasive DCIS is the structural 
integrity of the basement membrane, where tumor cells are encapsulated and 
restricted to the mammary gland. The transition into IDC is defined by basement 
membrane breakdown and tumor cells invasion into neighboring tissues. The fact 
that VAPB evokes similar behaviors in breast tumor cells (i.e. loss of basement 
membrane integrity and increased cell invasion) warrants further investigation of 
VAPB function during metastatic progression in vivo.  
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CHAPTER IV 
 
VAMP-ASSOCIATED PROTEIN B (VAPB) PROMOTES  
BREAST TUMOR GROWTH BY MODULATING THE  
PROTEIN SECRETORY PATHWAY  
 
 
Introduction 
Aberrant vesicle trafficking affects pathogenesis of many diseases, 
including cancer (Aridor & Hannan, 2000).  Dysregulated endocytosis of growth 
factor receptors and cadherin based adhesion complexes often promotes tumor 
growth (Mosesson et al, 2008). Conversely, the protein secretory pathway is 
increasingly recognized for its importance in tumor initiation and progression 
(Chan & Weber, 2002; Palmer et al, 2002; Vadlamudi et al, 2000). Secretion of 
growth factors, cytokines, matrix metalloproteinases, and delivery of receptors to 
the cell surface, facilitate tumor growth and invasion (Hanahan & Weinberg, 
2011), and all rely on protein trafficking. The dependence of tumor cells on 
protein and vesicle trafficking provides unique opportunities for cancer 
therapeutics aimed at mediators of trafficking (Wright, 2008). 
Most eukaryotic proteins that are destined for release into the extracellular 
space or for insertion into the plasma membrane are transported via an 
ER/Golgi-dependent vesicle secretory pathway. Small GTPases such as Rabs 
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and Arfs have emerged as key regulators in vesicle trafficking, involved in the 
multi-step process of vesicle formation, scission, motility, tethering, and fusion as 
diagrammed in Figure 4.1 (Segev, 2011). Select members of the Arf family 
function to recruit effector proteins, such as coat proteins, to newly budding 
vesicles in the ER and Golgi (Gillingham & Munro, 2007), whereas Rab proteins 
target cargo-loaded vesicles to the correct membrane destination (Stenmark, 
2009). Although Arf/Rab proteins can function in both endocytosis and 
exocytosis, the primary function of Arf1 and Rab1 appears to regulate vesicle-
mediated protein secretion (D'Souza-Schorey & Chavrier, 2006; Stenmark, 
2009).  
Vesicle associated membrane protein associated protein B (VAPB) is a 
highly conserved type II integral membrane protein that belongs to the VAP 
protein family (Nishimura et al, 1999; Weir et al, 1998) and primarily localizes to 
the ER and cis-Golgi (Moumen et al, 2011; Skehel et al, 2000). Although the 
yeast homolog of VAPB was shown to play critical roles in lipid homeostasis 
(Kagiwada et al, 1998), multiple studies in higher eukaryotic species demonstrate 
a function in protein transport along the secretory pathway. The first VAP protein 
(VAP-33) was proposed to function in neurotransmitter exocytosis (Skehel et al, 
1995) and further studies demonstrated the presence of VAP-33 on TGFα 
containing exocyst vesicles (Cao et al, 2008). The rat homolog of VAP-33, EGR-
30, was shown to function in early secretory protein transport mediated by COPI 
vesicles (Soussan et al, 1999). Despite the importance of vesicle-mediated 
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Figure 4.1. A diagram of GTPase families that regulate vesicle trafficking 
sub-steps. Vesicle formation is regulated by Arfs; vesicle scission by dynamin; 
vesicle motility by Rabs; vesicle tethering by Rabs and Rhos, and vesicle fusion 
by Rhos. [Image reproduced from (Segev, 2011)].
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protein secretion in tumor growth, the role of VAPB in cancer has not been 
investigated thus far.  However, a genome-wide microarray analysis of 50 human 
breast cancer cell lines and 145 clinical specimens revealed that VAPB is often 
amplified or overexpressed in breast cancer (Chin et al, 2006; Neve et al, 2006), 
suggesting the potential importance of VAPB function in human cancer. 
 In this report, we tested the potential contribution of protein secretion in 
VAPB’s growth-enhancing effects in breast tumor cells. We found that VAPB 
regulates breast tumor cell proliferation by modulating vesicle-mediated transport 
from the ER/Golgi network to the plasma membrane, partly through an Arf1 small 
GTPase-dependent mechanism. This data highlights the potential for targeting 
vesicle trafficking as a novel therapeutic approach in cancer. 
 
Materials and Methods 
 
Antibodies and Reagents 
Antibodies against the following proteins were used: anti-Arf1 (Arfs1A9/5), 
and agarose-congugated anti-HA for immunoprecipitation studies (Santa Cruz 
Biotechnologies), anti-HA (Sigma), anti-MYC, anti-cleaved caspase-3 (Cell 
Signaling Technologies) and anti-VSVG (8G5F11) (KeraFast). C-terminus tagged 
VAPB-Myc or Arf1-HA and FLAG-Rab1b was subcloned into pCLSXN_Neo 
(Addgene) or pCDNA3. 1 (Invitrogen) using cDNAs obtained from the Vanderbilt 
Microarray Core. Growth factor-reduced Matrigel were purchased from BD 
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Biosciences. Cell permeable crosslinkers (DSP and DTME) were purchased from 
Thermo Scientific.  
 
Cell culture 
Stable knockdown of VAPB in MMTV-Neu tumor cells was previously 
described (Chapter II). For re-expression of mutant VAPB, mutant constructs 
were subcloned into pCLSXN retroviral vector that contains a Neomycin 
resistance gene, allowing for G418 (300µg/mL for 6 days) selection in puromycin-
resistant populations. Viral supernatant was collected as described above from 
HEK 293T cells that were co-transfected with pCLSXN-Vector (10µg) only or 
pCLSXN-VAPB (10µg) and pCLAmpho plasmids (10µg) using Lipofectamine 
2000.  
MCF10A cells were obtained from American Type Culture Collection 
(ATCC) and cultured as previously described (Debnath et al, 2003). MCF10A-
HER2 cells were generated via retroviral transduction of the HER2 proto-
oncogene (Ueda et al, 2004).  Overexpression of WT or mutant VAPB in 
MCF10A-HER2 cells was achieved by infecting cells with pLXSN-Vector or -
VAPB retrovirus and selected in media containing 300µg/mL G418 for 6 days.  
 
Identification of VAPB-interacting proteins 
Proteins in complex with VAPB were identified using ReCLIP (Reversible 
Cross-Link Immuno-Precipitaiton) technology as previously described (Smith et 
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al, 2011). Briefly, to preserve physiological complexes, MMTV-Neu Vector or 
VAPB knockdown cells (KD #1) were treated with membrane permeable cross-
linkers (DSP and DTME) prior to lysis. DSP and DTME were first dissolved in 
DMSO (20nM) and then diluted in PBS (2mM).  DSP and DTME were mixed in a 
1:1 ratio, with a final concentration of 0.4mM in PBS. Cells were washed twice 
with PBS and incubated with the cross-linker mixture for 30 minutes at room 
temperature. The reaction was quenched for 10 minutes and cells were 
subsequently lysed and subjected to co-immunoprecipitation with anti-VAPB 
conjugated Protein G Dynabeads (Invitrogen). VAPB and its binding partners 
were eluted by incubating the beads at 37°C for 30 minutes in the presence of 
100mM DTT. For mass spectrometry analysis, the eluates were boiled for 5 
minutes in freshly prepared Laemmli sample buffer. Eluted and boiled proteins 
from MMTV-Neu vector and VAPB knockdown samples were trichloroacetic acid 
-precipitated and processed for shotgun analysis using Multidimensional Protein 
Identification Technology (MudPIT). Mass spectra data was analyzed using 
IDPICKER [2] software, an open-source protein assembly tool that derives a 
minimum protein list from peptide identifications filtered to a specified False 
Discovery Rate of less that 5%. This service was provided by the Mass 
Spectrometry Research Center at Vanderbilt University. 
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VSVG-GFP ts045 trafficking assays 
MCF10A-HER2 cells were transfected with VSV-G-GFP ts045 (generous 
gift from Dr. Jennifer Lippencott-Swartz) using Lipofectamine 2000. After 3 hours, 
transfection media was replaced with growth media and immediately incubated at 
40°C for an additional 16 hours. Cells were then treated with 100ug/mL 
cyclohexamide (Sigma-Aldrich) for 30 minutes prior to shift to 32°C at the 
indicated time points. For immunofluorescence analysis of VSVG-GFP, cells 
were plated on glass cover slips were rinsed in PBS, then fixed without 
permeabilization in 2% PFA for 15 minutes at room temperature and probed with 
ectodomain- specific anti-VSVG (1:1000).  
For biochemical analysis of surface VSVG-GFP, cells were labeled with 
Sulfo- NHS-LC-Biotin (Thermo Scientific) and processed as previously described 
[3]. Surface labeled proteins were pulled down using Streptavidin-agarose resin 
(Thermo Scientific) and subjected to western blot analysis. Cell surface and total 
VSVG protein was probed with monoclonal anti-VSVG (1:1000) and detected 
with anti-mouse HRP. Densitometry analysis for band intensity was performed 
using NIH Image J software. Cell surface VSVG was calculated as a percent of 
total VSVG. Data are derived from two independent experiments. 
 
Immunoblot, co-immunoprecipitation, and Arf1 pull-down assays 
For immunoblot analysis of VAPB knockdown or overexpression, cells 
were washed with PBS and lysed in Radioimmunoprecipitation Assay (RIPA) 
          76
buffer (50mM Tris pH 7.4, 150mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% 
SDS) supplemented with protease and phosphatase inhibitor tablets (Roche). 
Approximately 30-50ug of total cell lysate was separated by SDS-PAGE and 
probed with anti-VAPB (1:1000) overnight in 5% nonfat dry milk/ TBS-Tween 
(0.05%) and detected with anti-goat HRP (1:1000).  VAPB and Arf1 co-
immunoprecipitation in HEK 293T cells was performed with the addition of 2mM 
DSP (dithiobis (succinimidyl propionate), a reversible chemical cross linker and 
processed as previously described (Amarilio et al, 2005). 
 For Arf1 activity assay, 2 x 106 MCF10A-HER2 vector or VAPB-expressing 
cells were plated into 10 cm dishes and serum-starved for 6 hours. Cells were 
briefly rinsed once with PBS and then lysed in ice-cold lysis buffer. Samples were 
briefly vortexed, incubated for 15 minutes on ice, then centrifuged at 16,000 x g 
for 15 min at 4°C. GST-GGA3-PBD coupled to glutathione-Sepharose 4B was 
added to each tube, and the samples were rotated at 4 °C overnight. Proteins 
were eluted in 50 μl of SDS-sample buffer and boiled for 5 min. Proteins were 
separated on a 12% SDS-PAGE gel. Detection of Arf1-GTP was performed with 
immunoblot analysis using anti-Arf1. Densitometry analysis of percent Arf1-GTP 
was calculated using NIH Image J software.  
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Results 
 
Functional diversity of candidate VAPB-interacting proteins 
Many of VAPB’s proposed cellular functions are in relation to VAPB-
interacting proteins as summarized in Table 1. To gain molecular insights on how 
VAPB functions in breast tumor cells, we utilized the ReCLIP-coupled mass 
spectrometry-based proteomics approach (Multidimensional Protein Identification 
Technology) to identify novel VAPB interacting proteins. This approach not only 
preserves labile protein complexes but also greatly reduces background prior to 
proteomics analysis (Smith et al, 2011). Figure 4.2A is the western analysis of 
VAPB immunoprecipitation that was used for mass spectrometry.  
Using PANTHER (Mi & Thomas, 2009) we discovered functional diversity 
among the 170 candidate VAPB-interacting proteins (Figure 4.2B) with 11 distinct 
biological processes including protein modification, carbohydrate metabolism, 
and lipid transport. These proteins were selected based on a greater than four- 
fold enrichment in the vector control cells relative to VAPB knockdown cells. 
These proteins include previously reported VAPB-interacting proteins, such as 
membrane associated phosphatidylinositol transfer protein 1 (Nir2) (Amarilio et 
al., 2005) and Oxysterol binding protein 1 (OSBP) (Wyles et al., 2002) (Table 3), 
thus validating the approach. We identified several biological processes including 
vesicle trafficking, protein modification, and cell-cell/matrix adhesion. Additionally, 
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Figure 4.2. Functional diversity of candidate VAPB-binding proteins. 
MMTV-Neu control or VAPB knockdown cells were treated with chemical cross-
linkers prior to lysis. (A) MMTV-Neu tumor cell lysates were immunoprecipi-
tated with anti-VAPB conjugated beads and the resulting protein complexes 
were subjected to mass spectrometry analysis. The following criteria were used 
for selection of candidate proteins: (1) spectral counts ≥ 5 and (2) the ratio of 
vector/ knockdown ≥ 4. (B) Candidate proteins were classified based on 
biological processes as annotated in PANTHER (Mi & Thomas, 2009). 
Selected functional groups and proteins are listed in Table 3.
Ve
cto
r
KD
 #
1
CL
Ve
cto
r 
Ve
cto
r 
KD
 #
1 
IgG anti-VAPB
IP
VAPB
          79
Ras Family of  Small GTPases Vector KD #1
ADP-ribosylation factor 1;Arf1 22 5
ADP-ribosylation factor 3;Arf3 22 5
Ras-related protein Rab-7a;Rab7a 21 2
ADP-ribosylation factor 5;Arf5 19 2
Ras-related protein Rab-18;Rab18 18 1
Ras-related protein Rab-1A;Rab1A 12 3
Ras-related protein Rab-5C;Rab5c 11 2
Ras-related protein Rab-1B;Rab1b 10 2
Ras-related protein Rab-5A;Rab5a 9 2
Ras-related protein Rab-5B;Rab5b 8 1
Ras-related protein Rab-8A;Rab8a 7 1
Ras-related protein Rap-1b;Rap1b 6 1
Ras-related protein Rap-1A;Rap1a 6 1
Vesicle Trafficking Related Proteins Vector KD #1
VAMP-associated protein B;Vapb 127 31
VAMP-associated protein A;Vapa 39 1
Vesicle-trafficking protein SEC22b;Sec22b 12 1
Rab GDP dissociation inhibitor beta;Gdi2 10 0
ADP-ribosylation factor-like protein 1;Arl1 6 0
Sec1 family domain-containing protein 1;Scfd1 5 0
Lipid Transport Vector KD #1
Oxysterol-binding protein 1;Osbp 19 3
1-acylglycerophosphocholine O-acyltransferase 1;Lpcat1 13 3
Membrane-associated phosphatidylinositol transfer protein 1;Pitpnm1 (Nir2) 9 0
Phosphatidylinositol transfer protein beta isoform;Pitpnb 8 1
Long-chain fatty acid transport protein 4;Slc27a4 6 0
Protein Modification Vector KD #1
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2;Rpn2 26 17
Protein disulfide-isomerase A6;Pdia6 24 6
E3 ubiquitin-protein ligase NEDD4;Nedd4 18 2
UDP-glucose:glycoprotein glucosyltransferase 1;Ugcgl1 18 2
Phosphatidylinositide phosphatase SAC1;Sacm1l 14 2
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit;Ddost 10 2
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3A;Stt3a 9 8
Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform;Ppp3ca 5 0
Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform;Ppp2cb 5 0
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform;Ppp2ca 5 0
Serine/threonine-protein kinase 3;Stk3 5 1
Glycylpeptide N-tetradecanoyltransferase 1;Nmt1 5 0
Cell-cell or Cell-Matrix Adhesion and Motility Vector KD #1
Profilin-1;Pfn1 24 4
Integrin beta-4;Itgb4 12 0
Ezrin;Ezr 9 1
Inverted formin-2;Inf2 8 2
Integrin beta-1;Itgb1 6 0
Table 3. Selected functional groups of candidate VAPB-interacting proteins
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analysis revealed that VAPB interacts with a group of small GTPases, including 
Arf1, Arf3, Arf5, Rab1, and Rab8 proteins (Table 3). 
 
VAPB facilitates the transport of proteins to cell surface 
Because the primary functions of Arf1/3 (Spang, 2002; Stearns et al, 
1990) and Rab1/8 (Huber et al, 1993; Plutner et al, 1991) small GTPases are to 
regulate vesicle trafficking in the secretory pathway, we assessed whether VAPB 
regulates vesicle-mediated protein transport from the ER/Golgi to the plasma 
membrane.  Control or VAPB expressing MCF10A-HER2 cells were transfected 
with a temperature sensitive mutant of vesicular stomatitis viral protein G (ts045-
VSVG)-GFP (Presley et al, 1997), commonly used to visualize secretory protein 
transport (Griffiths et al, 1985). At higher temperatures (40°C), ts045-VSVG-GFP 
mis-folds and is retained in the ER. Upon temperature reduction (32°C), VSVG-
GFP folds rapidly and is transported from the ER/Golgi network to plasma 
membrane. As shown in Figure 4.2, MCF10A-HER2 cells that overexpress VAPB 
displayed enhanced VSVG-GFP trafficking to the plasma membrane. By 30 
minutes MCF10A-HER2-VAPB cells display VSVG protein at the cell surface 
(red) as indicated using an antibody that specifically recognizes extracellular 
VSVG (Figure 4.3A). Surface biotinylation assays revealed a significant increase 
in amount of VSVG protein at the cell surface in VAPB overexpressing cells 
compared to vector control cells (Figure 4.3B). Taken together these data 
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Figure 4.3. VAPB facilitates the transport of secretory proteins to cell 
surface. (A) MCF10A-HER2-VAPB expressing cells were transfected with the 
ts045 temperature sensitive vesicular stomatitis viral glycoprotein (VSVG) GFP 
and incubated at 40°C for 16 hours to accumulate misfolded VSVG protein in 
the ER. Following a 30-minute incubation with cyclohexamide, the cells were 
shifted to a permissive temperature (32°C) to allow transport along the secre-
tory pathway. Total VSVG was visualized by GFP fluorescence (green) and cell 
surface VSVG was detected using an antibody against VSVG ectodomain (red) 
under non-permeable condition. (B) The kinetics of appearance of VSVG-GFP 
at the cell surface was measured by cell-surface biotinylation and subsequent 
quantification of immnoblots with anti-VSVG in two independent experiments (p 
< 0.05, unpaired t test).
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indicate that VAPB expression mediates protein transport to the plasma 
membrane.  
 
VAPB-dependent tumor growth is partly mediated by Arf1 small GTPase.  
To dissect molecular mechanisms by which VAPB regulates vesicle-
mediated protein secretion in tumor cells, we focused on small GTPase Arf1 
because of Arf1’s well-recognized function in secretory transport (Spang, 2002).   
To test physical interaction between VAPB and Arf1, we transfected 293T cells 
with Myc-tagged VAPB and HA-tagged Arf1 and immunoprecipitated cell lysates 
with anti-Myc-conjugated beads.  As shown in Figure 4.4A, the Arf1 protein was 
readily detected in anti-Myc immunoprecipitates.  The co-immunoprecipitation of 
Arf1 with VAPB was dependent on the expression of both VAPB and Arf1, was 
reduced markedly in cells transfected with Arf1 only, and was undetectable in 
control cells (left panel).  Conversely, VAPB was also readily detected in anti-HA 
immunoprecipitates in cells transfected with both VAPB and Arf1, but not in those 
transfected with VAPB alone or control cells (right panel).  
Next, we determined whether Arf1 activity is affected by VAPB expression. 
Similar to most small GTPases, Arf1 cycles between a GTP-bound “active” state 
and GDP-bound “inactive state. Active Arf1 has several downstream effectors, 
including coatamer proteins that facilitate budding of transport vesicles. Using a 
GST fusion protein of the GGA3, a known Arf-GTP binding protein, we were able 
to “pull-down” activated Arf1-GTP in MCF10-HER2 cells. Overexpression of 
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Figure 4.4. VAPB physically interacts with Arf1 GTPase and increases Arf1 
activity. (A) HEK 293T cells were transfected with VAPB-Myc and/ or Arf1-HA 
expression constructs. VAPB or Arf1 was immunoprecipitated from cell lysates 
and proteins were analyzed for Arf1 or VAPB, respectively. (B) Arf1-GTP was 
measured by an effector pull-down assay using GST-GGA3-PBD glutathione 
sepharose beads. Elevated Arf1-GTP level was observed in MCF10A-HER2 
cells overexpressing VAPB relative to vector control cells. Two independent 
experiments were performed (p < 0.05, t test).
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VAPB was sufficient to increase Arf1-GTP levels (Figure 4.4B), suggesting that 
VAPB regulates Arf1 activity.  
To investigate whether Arf1 is involved in VAPB-mediated protein 
secretion and tumor cell growth, we used an Arf inhibitor, Brefeldin A (BFA). BFA 
is a fungal metabolite that inhibits Arf guanine nucleotide exchange factors and 
prevents Arf-GTP formation (Donaldson et al, 1992). It is also well documented 
that BFA-treated cells reversibly inhibits secretory protein transport (Klausner et 
al, 1992). Accordingly, we investigated the effects of BFA treatment on spheroid 
growth in VAPB expressing cells. Two days after plating cells in 3D Matrigel 
culture, MMTV-Neu tumor cells or MCF10A-HER2 Vector or VAPB expressing 
cells were treated with vehicle or BFA. As expected, short-term treatment of cells 
with BFA significantly inhibited Arf1-GTP levels in MMTV-Neu cells (Figure 4.5A) 
and MCF10A-HER2 cells (Figure 4.5D). BFA treatment also significantly 
decreased spheroid size in both MMTV-Neu (Figure 4.5B) and MCF10A-HER2 
VAPB (Figure 4.5E) expressing cells and cell proliferation as quantified by Ki67 
staining at day 5 (Figure 4.5C and 4.5F).  These results suggest that VAPB-
dependent tumor growth is mediated partly by Arf1 small GTPase. 
 
Discussion 
 VAPB was originally identified as one of the vesicle-associated membrane 
protein (VAMP) associated proteins, which functions in a wide range of cellular 
processes. In mammalian cells, VAPB appears to be involved in lipid transfer and 
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Figure 4.5. Arf inhibitor Brefeldin A reduces spheroid size in VAPB 
expressing tumor cells.  MMTV-Neu and MCF10A-HER2 cells grown in 3D 
Matrigel were treated with BFA for 9 days at the concentration of 500nM and 
125nM, respectively.  Arf1-GTP levels were measured by GST-GGA3-PBD 
pull-down assay (A&D).  Tumor cell spheroid size was quantified using Image J. 
(p <0.05; single factor ANOVA) (B&E). Tumor cell proliferation was measured by 
immunofluorescence using an antibody against PCNA, a cell proliferation marker 
(C&F).  Percentage of PCNA positive nuclei (red) was quantified at day 5 in 
MMTV-Neu cells (C) and MCF10A-Her2 cells (F). 
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vesicle trafficking (Amarilio et al, 2005; Lev et al, 2008; Peretti et al, 2008). 
Increased copy numbers and expression levels of the VAPB gene were reported 
in human breast cancer cells and clinical tumor specimens (Arriola et al, 2008; 
Chin et al, 2006; Neve et al, 2006). However, VAPB function in tumor cells is 
poorly understood.  In this study, we showed that VAPB regulates tumor cell 
growth in both cell culture and animal models (Chapter II). Moreover, our data 
indicate that one mechanism leading to the phenotype is modulation of Arf1 small 
GTPase-dependent vesicle-mediated protein secretion by VAPB. Collectively, the 
analyses provide genetic, functional and mechanistic evidence that VAPB 
promotes tumor cell proliferation by regulating vesicle-mediated protein traffic 
from ER-Golgi to plasma membrane. 
Studies in S. cerevisiae have established the importance of Arf1 in 
secretory membrane transport (Stearns et al, 1990).  Subsequent studies 
showed that Arf1 GTPase regulates coat assembly during vesicle formation, both 
from the Golgi to the ER and between Golgi cisternae (D'Souza-Schorey & 
Chavrier, 2006; Gillingham & Munro, 2007; Spang, 2002).  Several lines of 
evidence suggest that one mechanism by which VAPB regulates vesicle-
dependent protein secretion is through modulating Arf1 activity.  First, Arf1 can 
physically interact with VAPB and regulate the levels of Arf1-GTP, which serves 
to recruit effectors, such as coatamer protein I, AP1 and GGAs to the Golgi and 
mediate vesicle formation (Spang, 2002).  In addition, Brefeldin A, which inhibits 
the formation of Arf-GTP and secretory protein transport, inhibited tumor cell 
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proliferation in 3-dimentional cell culture. It is also possible that VAPB regulates 
more than one of these small GTPases. We found that VAPB was also able to 
interact with Rab1b in HEK 293T cells, another mediator of secretory vesicle 
formation (Dugan et al, 1995) (Figure 4.6). Aside from Arf1 and Rab1b, Mass 
Spectrometry analysis also identified Arf3, Arf5, and Rab8 small GTPases as 
potential VAPB-interact partners, all of which have proposed functions secretory 
vesicle traffic. (Bonifacino & Glick, 2004; D'Souza-Schorey & Chavrier, 2006; 
Huber et al, 1993; Plutner et al, 1991). Given that tumor cells heavily rely on 
growth factor secretion and receptor localization to the plasma membrane the 
functional significance of these interactions needs further investigation.  
 While, our results suggest that VAPB enhances breast tumor cell 
proliferation through enhanced secretory vesicle trafficking, we cannot rule out 
the possibility that aberrant VAPB expression dysregulates other vesicle 
trafficking events such as endocytosis. From our screen, we also identified Rab5 
(Table 3), a small GTPase enriched on early endosomes (EE) which are focal 
points of the endocytic pathway [Reviewed in (Jovic et al, 2010)]. Rab5 was also 
found to regulate endocytosis and recycling of β-integrins (Pellinen et al, 2006). 
Interestingly, we identified Integrinβ1 and Integrinβ4 as a candidate VAPB 
interacting proteins (Table 3). The fact that VAPB also localizes plasma 
membrane (Figure 3.5), where endocytosis is often initiated, only strengthens the 
rationale for investigating the functional significance VAPB-Rab5 or VAPB-β-
Integrin interactions in breast tumor proliferation and invasion.  
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Figure 4.6. VAPB interacts with Rab1 in HEK 293 cells. HEK 293T cells 
were transfected with VAPB-Myc and/ or FLAG-Rab1 expression constructs. 
VAPB or Rab1 was immunoprecipitated from cell lysates and the resulting 
protein complexes were analyzed by western blot for Rab1 or VAPB, respec-
tively. VAPB physically associated with Rab1 when both VAPB and Rab1 
were expressed in 293 cells.
          91
Our previous studies demonstrated a functional role of VAPB in promoting 
tumor cell proliferation in breast cancer (Chapter II). Moreover we have identified 
various VAPB interacting proteins of diverse function. It is tempting to speculate 
that VAPB may represent a common mechanism by which many pathways 
including secretory protein transport converge to promote tumor growth. This 
discovery opens up a number of exciting avenues for future studies of VAPB in 
cancer. Additionally targeting the VAPB-associated protein secretory pathway 
may provide novel targets for future pharmacological strategies in cancer 
therapy. 
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CHAPTER V 
 
THE ROLE OF  
VAMP-ASSOCIATED PROTEIN B (VAPB) 
IN TUMOR GROWTH, IN VIVO 
 
Introduction 
 Analysis of human breast cancer dataset and tissue microarray indicates 
that VAPB is often overexpressed in tumors and that high VAPB-expression is 
associated with poor patient survival (Figure 1.2). Consistent with our data, 
several other laboratories also demonstrated VAPB gene amplification in patient 
breast cancer samples (Chin et al, 2006; Neve et al, 2006). VAPB expression is 
also elevated in a breast cancer cell culture model of pre-invasive to invasive 
transition (Rizki et al, 2008). This evidence highlights the clinical relevance of 
VAPB in human breast cancer.  
Although our previous study shows that VAPB enhances tumor growth in 
vitro (Chapter II), functional validation of VAPB in a mouse model of breast 
cancer is needed. At present VAPB animal models are limited to the 
understanding of neurodegenerative disorders. Tudor et al., generated two 
transgenic mouse lines that express WT-VAPB or P56S-VAPB specifically in 
motor neurons. Analyses of both sets of mice revealed no overt motor or 
behavioral dysfunction (Tudor et al, 2010). However the mutant mice developed 
early signs of neuronal abnormalities associated with ALS, marked by P56S-
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VAPB protein aggregates similar to results found in cell culture (Tudor et al, 
2010). 
To investigate the consequences of VAPB deficiency in transgenic models 
of breast cancer, we crossed VAPB knockout/LacZ knockin (VAPB KO) mice with 
the MMTV-NeuT mouse-model of spontaneous mammary tumor formation. In 
this model, the MMTV-LTR drives the expression of activated Neu, the rat 
homolog of ErbB2 with a single amino acid substitution, specifically in the 
mammary gland epithelium (Muller et al, 1988). This model recapitulates multi-
step tumor progression similar to that observed in human breast cancer. Given 
that VAPB deficiency reduces growth in MMTV-Neu tumor cells, we anticipate 
that VAPB deficiency will impair tumor growth in MMTV-NeuT/VAPB KO mice. 
Indeed our supporting data will show decreased tumor number and tumor burden 
in VAPB KO animals, highlighting the importance of VAPB in breast cancer. 
 
Materials and Methods 
 
Mice and in vivo tumor studies 
All animals were housed under pathogen-free conditions, and experiments 
were performed in accordance with AAALAC guidelines and with Vanderbilt 
University Institutional Animal Care and Use Committee approval. VAPB 
knockout/ LacZ knock-in mice were generated by ingenious Targeting 
Laboratories (Ronkonkoma, NY). The VAPB allele was disrupted with the 
insertion of a lacZ reporter gene in. VAPB KO/ LacZ knockin clones (129/ SvEv 
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ES cells) were selected and injected into C57BL/6 mouse blastocysts. 129/ Bl6-
hybrind, VAPB KO mice were backcrossed with FVB animals for three 
generations prior to crossing with MMTV-NeuT mice (generous gift from Dr. 
Guido Fiorni), inbred in an FVB background. VAPB WT or KO mice were 
identified by PCR analysis of genomic DNA isolated from ear digests using the 
following primers: WT (forward) - TCG AGC CAC AAC ACG AGC TCA - 3′; KO (forward) 
- GCA TAA GCT TGG ATC CGT TCT TCG GAC - 3′; WT or KO (reverse) 5′ - AGT GTG CAC 
GGG CTT CGT GG - 3′. The NeuT transgene was detected by PCR using primers 
(forward 5′ - CCC CGG GAG TAT GTG AGT GA - 3′; reverse 5′ - TGA GCT GTT TTG 
AGG CTG ACA - 3′) under conditions recommended by Jackson Laboratories (Bar 
Harbor, ME). Littermate NeuT-positive VAPB WT and KO mice were sacrificed at 
5 months for tumor analysis. Tumors were collected, enumerated and 
dimensions were measured by caliper. Tumor volume was calculated as 
previously described (Brantley-Sieders et al, 2008).  
 
Histological analysis 
Mammary glands were harvested and fixed in 10% NBF. Whole-mount 
H&E analysis of mammary glands was performed as previously described 
(Brantley-Sieders et al, 2008). Whole-mount hematoxylin staining of mammary 
glands was performed by fixing the number 4 inguinal mammary glands in 10% 
buffered formalin (Fisher, SF93-4) overnight at 4°C. The glands were incuvated 
in acetone in order to dissolve the fat, equilibrated into 100% ethanol, and 
stained in Mayer's hematoxylin solution (VWR Scientific, West Chester, PA) for 
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one hour at room temperature, light protected. Glands were de-stained in tap 
water, followed by 50% ethanol acidified with hydrochloric acid (0.05M). The 
glands were then dehydrated in a graded ethanol series followed by xylenes, and 
mounted on slides for photodocumentation. Branch points were quantified as 
previously described (Vaught et al, 2009) 
 
Western analysis of mammary glands and tumors 
Harvested mammary glands or tumors were mechanically homogenized in 
Radioimmunoprecipitation Assay (RIPA) buffer (50mM Tris pH 7.4, 150mM NaCl, 
1% NP-40, 0.5% deoxycholic acid, 0.1% SDS) supplemented with protease and 
phosphatase inhibitor tablets (Roche). Protein were resolved on SDS page gel 
and analyzed by western blot for VAPB, actin, or ErbB2 (Neu). 
 
Results 
 
VAPB deficient mice exhibit normal mammary gland architecture. 
 Our own studies revealed that VAPB promotes tumor cell proliferation in 
cell culture (Chapter II). However whether these phenotypes are reproducible in 
an animal model of breast cancer remain unknown. Therefore we generated 
(inGenious Targeting Laboratory) VAPB KO mice in order to test the function of 
VAPB in tumor cell growth in vivo. The targeting strategy and confirmation of 
genotype by southern blot are shown in Figure 5.1A and B. After backcrossing 
mice into the FVB background, we confirmed VAPB deficiency by western 
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Figure 5.1. Generation of VAPB knockout/ LacZ knockin mice. (A) Target-
ing strategy. (B) Southern blotting analysis to reconfirm positive clones first 
identified by PCR in ES cells. Lanes 1-3 is DNA from C57Bl(6), 129/ SzEv, and 
B6 X 129 hybrid, respectively. (C) Breeding strategy to generate VAPB WT or 
VAPB KO mice that are positive for the NeuT transgene. 
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analysis. As expected VAPB protein was undetectable from whole mammary 
gland lysates from VAPB KO mice when compared with littermate WT controls 
(Figure 5.2 A).  
To determine whether VAPB deletion affects mammary gland architecture, 
we performed whole mount analysis of WT and VAPB KO mammary glands at 8 
weeks of age. We observed no gross morphological changes in the outgrowth of 
epithelial cells into the fat pad (Figure 5.2B) and in number of epithelial branch 
points as quantified in Figure 5.2 C. These results suggest that VAPB deficiency 
is not critical to mammary gland development under these conditions. 
 
Reduced tumor number in MMTV/NeuT VAPB KO mice  
 To investigate the influence of VAPB expression on mammary tumor 
formation, we crossed VAPB knockout mice (FVB background) with MMTV-NeuT 
transgenic mice as diagrammed in Figure 5.1C. In this model, MMTV-LTR drives 
the expression Neu, the rat homolog of ErbB2 (HER2) along containing an 
activating mutation, specifically in the mammary gland. In this model, virgin, 
female mice develop tumors between 4-5 months of age (Muller et al, 1988). At 
five months, tumors that were harvested from MMTV-NeuT-positive, VAPB WT or 
KO mice were enumerated and scored for size. Not only do we see a significant 
decrease in the number of tumors formed per mouse (Figure 5.3A), we also 
observed a reduction in overall tumor burden in VAPB KO mice relative to WT 
controls (Figure 5.3 B). Western analysis of tumor lysates show that VAPB 
depletion in KO tumors, however protein expression levels of ErbB2 were not 
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Figure 5.2. Normal mammary gland morphology in VAPB deficient mice. 
(A) VAPB protein expression from mammary gland lysates was undetectable in 
KO mice  when compared to WT controls. (B) Whole-mount hematoxylin 
staining of number 4 inguinal mammary glands collected from VAPB WT and 
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Figure 5.3. VAPB deficiency results in reduced tumor number and 
burden. (A) MMTV-NeuT/ VAPB WT or KO mice were sacrificed at 5 months 
of age. Tumors were harvested, enumerated and scored for size (n=4). (A) 
Average number of tumors per mouse was significantly reduced with VAPB 
deficiency (p < 0.05 unpaired t-test). (B) Reduced tumor burden per mouse 
was observed in MMTV-NeuT/ VAPB KO mice. (C) Confirmation of VAPB 
protein in tumor lysates. 
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affected by VAPB deficiency (Figure 5.3 B). Our in vivo results are consistent 
with our observations that VAPB deficiency also reduces spheroid growth (Figure 
2.3 A) in cell culture. 
 
Discussion 
 Data from our cell culture models demonstrate that VAPB functions to 
promote tumor cell proliferation (Chapter II). Additionally, high VAPB expression 
correlates with poor prognosis in human breast cancers (Figure 1.2), 
demonstrating VAPB’s clinical significance. As an extension of these results and 
observations, we investigated the function of VAPB in a mouse model of 
spontaneous breast cancer, using the MMTV-NeuT model to maintain 
consistency with our cell culture models. Importantly, these mice form tumors in a 
manner similar to that seen in HER2-amplified human breast cancers (Muller et 
al, 1988). MMTV-NeuT/VAPB KO, female mice exhibited a reduction in tumor 
number and burden, consistent with reduced rate of tumor cell proliferation upon 
knockdown of VAPB in cell culture (Figure 2.3A).  
 While these data are consistent with the hypothesis that VAPB promotes 
tumor growth, further studies are required to understand the role of VAPB in early 
and late stages of breast tumor progression. To address the function of VAPB in 
tumor initiation, it would be of interest to examine pre-malignant changes in the 
mammary gland of MMTV-NeuT VAPB KO mice, including epithelial hyperplasia, 
proliferation and apoptosis prior to tumor formation. Along these lines tumor 
latency can be addressed by monitoring tumor formation in MMTV-NeuT, VAPB 
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KO mice by palpation. Since the VAPB knockout allele contains a LacZ knockin, 
one can determine the temporal and cell type expression of VAPB during tumor 
progression by staining tumor sections with X-gal from MMTV-NeuT mice.  
 Additionally, we also have data to suggest that VAPB promotes invasive 
behavior of breast tumor cells (Chapter III). At later stages of tumor progression, 
MMTV-NeuT mammary tumors progress from hyperplasia to metastatic 
carcinoma as tumor cells become increasingly motile and enter the blood stream 
or lymphatics, developing secondary metastatic tumors in the lung (Guy et al, 
1992). While our data presented here only implicates VAPB is important for 
tumor growth in vivo, further investigation is required to see VAPB expression is 
required for metastatic tumor growth. 
 Because the MMTV-NeuT VAPB-KO mice generated are whole-body 
knockouts, we cannot fully dissect the contribution of the tumor 
microenvironment to the reduced burden observed with VAPB deficiency. 
Therefore additional experiments are needed to address the function of VAPB in 
cell types that make up the tumor microenvironment. However, our in vivo results 
thus far provide strong rationale to pursue the above-mentioned experiments. 
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CHAPTER VI 
 
DISCUSSION AND  
FUTURE DIRECTIONS 
 
Discussion 
We recently observed that high expression VAPB in clinical breast cancer 
samples significantly correlated with reduced overall and relapse-free survival. 
Other laboratories have also reported similar results. A genome–wide microarray 
analysis of 50 human breast cancer cell lines and 145 clinical specimens 
revealed that VAPB is often amplified or overexpressed in breast cancer, and 
functions in metastasis initiation. VAPB is a member of the VAP family proteins 
that interact with a large number of intracellular proteins and known VAP 
functions include vesicle trafficking, lipid metabolism and transfer, and the 
unfolded protein response (UPR). In addition to VAPB’s intracellular function, it is 
cleaved and secreted, acting as a ligand for Eph receptor tyrosine kinases. 
Despite VAPB’s clinical relevance and its role in diverse cellular processes, the 
precise function of VAPB in breast cancer was poorly understood. Our work 
presented herein has advanced our understanding of VAPB in breast tumor cell 
proliferation and invasion. We identified two potential mechanisms by which 
VAPB promotes tumor growth and invasion (1) increased AKT activity and (2) 
enhanced vesicle secretion. 
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  Many breast cancers depend on the hyperactivation of AKT-PI3K for 
growth, evasion of apoptosis, and invasion (Miller et al, 2011; Vivanco & 
Sawyers, 2002). We provide evidence that VAPB regulates breast tumor cell 
proliferation and invasion through AKT activation. Overexpression of VAPB in 
MCF10A-HER2 cells enhances phosphorylation of AKT.  In contrast, knockdown 
of VAPB in MMTV-Neu tumor cells diminishes pAKT levels. Moreover, 
pharmacological inhibition of AKT significantly reduced three-dimensional 
spheroid growth induced by VAPB and invasion through Transwell filters. 
Although these results do not rule out the contribution of other signaling 
pathways that modulate cell proliferation, our evidence suggests that VAPB 
induces growth and invasion through AKT activation. 
 We also report that VAPB modulates vesicle-mediated protein secretion. 
In doing so, it is possible that VAPB directly enhances tumor growth. Tumor cells 
rely on vesicle-mediated transport for receptor localization and growth factor 
secretion. Immunoprecipitation-coupled mass spectrometry analysis identified 
candidate VAPB-interacting proteins in cancer cells, including Arf1, a small 
GTPase involved in secretory protein transport. VAPB physically interacts with 
Arf1 and VAPB overexpression enhances trafficking of vesicular stomatitis virus 
glycoprotein (VSVG) to the cell surface. Inhibiting the secretory pathway with an 
Arf inhibitor, Brefeldin A, reduced tumor spheroid size and proliferation. While 
these data suggest that Arf1 is at least one major component of VAPB-mediated 
          104
vesicle trafficking in breast cancer, they do not rule out the possibility of other 
vesicle trafficking pathways such as endocytosis.  
Dysregulated endocytosis of growth factor receptors and cadherin-based 
adhesion complexes often promotes tumor growth (Mosesson et al, 2008). 
Further investigation is needed to determine whether VAPB expression can 
prevent receptor downregulation, potentially sustaining mitogenic signaling 
pathways. It would also be of great interest to determine whether increased 
secretory transport observed with VAPB expression also contributes to AKT 
activation, potentially through autocrine or paracrine mechanisms.  
 
Future Directions 
While our work implicates two mechanisms by which VAPB promotes 
breast tumor growth or invasion, further investigation is required to reveal VAPB’s 
full potential in cancer. We are confident that continued work in this field of study 
will provide novel insights into breast cancer progression. We attempt to 
speculate on a few possibilities below.  
 
Does secreted VAPB (MSP) contribute to breast tumor growth? 
MSP was discovered in C. elegans, where it was associated with both cell 
motility and fertility (Miller et al, 2001). In humans, the Major Sperm Protein 
(MSP) domain of VAPB was shown to be cleaved, secreted and able to bind to 
Eph receptors (Tsuda et al, 2008). We were able to detect soluble MSP in the 
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conditioned media in several breast cancer cell lines by western analysis (Figure 
6.1A). Furthermore, MSP is detectable in human serum (Tsuda et al, 2008).  
The Eph family of RTKs has recently been shown to play an important role 
in breast cancer (Duxbury et al, 2004; Zelinski et al, 2001). Eph receptors are 
divided into Class A and Class B receptors, based on their binding affinity to two 
distinct types of membrane bound ligands known as ephrins. Specifically, the 
EphA2 receptor is aberrantly over-expressed in 60-80% of mammary carcinomas 
verses relative to normal breast tissue, and EphA2 overexpression is associated 
with poor patient survival (Fournier et al, 2006; Martin et al, 2008). One model 
suggests that in normal cells, intact cell-cell contact allows EphA2 to bind with its 
ligand, ephrinA1. This interaction promotes phosphorylation and activates 
EphA2, reducing ERK phosphorylation. ERK signaling is a major pathway 
regulating cell proliferation. In breast cancer, EphA2 overexpression and lack of 
interaction with ephrinA1 can promote tumor growth by activating MAPK. 
EphA2’s oncogenic effects appear to be ligand independent. However, the recent 
discovery of active soluble ephrin-A1 ligand in tumor cells poses a challenge to 
this model (Wykosky et al, 2008), as soluble ligand should be able to activate 
receptor in the absence of cell-cell contact. Accordingly, it is possible that tumor 
cells may secrete an antagonist to compete with ephrin-A1 ligand for binding to 
the EphA2 receptor as modeled in Figure 6.1B. Therefore further studies are 
needed to dissect the effects of MSP versus full-length VAPB on breast tumor 
cells. 
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Figure 6.1.  Potential role of secreted VAPB (MSP) in cancer. (A) 
VAPB-MSP is detectable in tumor cell conditioned media, using the 
same VAPB antibody used to detect full-length VAPB protein. (B) 
Working model for VAPB-MSP in Eph receptor function of tumor 
promotion versus tumor supression [Adapted from (Vaught et al., 
2008)].
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How does VAPB modulate AKT activity? 
Although we demonstrate that VAPB enhances breast tumor cell 
proliferation and invasion, at least in-part, through the AKT pathway, the exact 
mechanism by which this happens remains unknown. There are several steps 
leading to AKT phosphorylation, starting with phosphoinositide 3-kinase (PI3K) 
activation upon recruitment to autophosphorylated, ligand-activated receptor 
tyrosine kinases (RTKs) (Vivanco & Sawyers, 2002). PI3K is a lipid kinase that 
catalyzes the synthesis of membrane phosphatidylinositol-3,4,5-P3 (PIP3) from 
phosphatidylinositol-4,5-P2 (PIP2). The generation of PIP3 on the inner leaflet of 
the plasma membrane recruits AKT by direct interaction with its PH domain 
(Vivanco & Sawyers, 2002). At the membrane, another PH-domain-containing 
serine/threonine kinase named PDK1 phosphorylates AKT on Thr308 (Stokoe et 
al, 1997) and while mTORC2 mediates phosphorylation of Ser473 (Sarbassov et 
al, 2005).  
Given the effects of VAPB on breast tumor cell proliferation and invasion is 
dependent on AKT activation, it would be interesting to examine how VAPB 
modulates upstream activators of AKT, such as PI3K, both at the level of 
recruitment to RTKs and PI3K activity. In this study it is also noteworthy that 
VAPB interacts with Arf1, a small, Ras-family GTP-ase. Interestingly, Arf1 has 
been implicated in the recruitment of the p85 subunit of PI3K to EGFR in breast 
cancer cells (Boulay et al, 2008). This raises the possibility that the VAPB/ Arf1 
interaction enhances PI3K activity by promoting recruitment of its p85 subunit.  
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On the other hand, if VAPB does not affect AKT activation at the level of 
PI3K, it is possible that VAPB alters the availability of PI3K’s intracellular 
substrate PIP2 at the plasma membrane. We can speculate on this idea because 
we, and others, have found that VAPB interacts with Nir2 (PITPB2), a 
phosphoinositol transfer protein [Table 3; (Litvak et al, 2005; Peretti et al, 2008)]. 
These proteins facilitate the transfer of phosphoinositols between various cell 
membrane interfaces. Nir2 has been proposed to target PIs from the ER to trans-
Golgi PI4-kinases (Schaaf et al, 2008) ultimately generating PtdIns(4)Ps at the 
Golgi. However, recent studies indicate that the majority of PtdIns(4)P resides in 
the plasma membrane (Hammond et al, 2009), which is then converted to PIP2 
by phosphatidylinositol 4-phosphate 5-kinases (PIP5Ks) (Fruman et al, 1998). It 
is tempting to speculate that VAPB promotes AKT by elevating levels of PIP2 
substrate for PI3K, perhaps through localized targeting of phosphoinositide (PIs) 
intermediates by Nir2. 
 
Does VAPB relieve ER stress during tumor proliferation?  
 Proliferative tumor cells often hijack various cellular processes in order to 
support growth, exerting stress on organelles such as the ER which is the site of 
protein folding and secretion, lipid biosynthesis and calcium homeostasis (Tsai & 
Weissman, 2010). Tumor cells face extracellular stresses such as hypoxia, 
nutrient deprivation or growth constraints by the extracellular matrix (ECM) as 
well as intracellular stresses such as high protein demand for growth factors and 
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receptors (Tsai & Weissman, 2010). Such harsh conditions activate the UPR 
through one or all three receptors (IRE1, ATF6 and PERK).  
Evidence has emerged that VAPB activates the IRE1-XBP1 arm of the 
UPR (Kanekura et al, 2006). Furthermore sustained IRE1-XBP1 activation has 
been shown to help cells enhance proliferation and evade cell death (Lin et al, 
2007; Lin et al, 2009). Interestingly the IRE1-XBP1 pathway has been implicated 
in breast cancer such that XBP1 expression is upregulated in certain breast 
cancers and correlates with poor prognosis in patients (Davies et al, 2008; 
Fujimoto et al, 2003). Additionally, in vitro studies have demonstrated that XBP1 
confers resistance to apoptosis in breast cancer cell lines (Gomez et al, 2007). A 
role for the IRE1-XBP1 pathway in breast cancer is further supported by in vivo 
bioluminescence imaging of breast tumor cells expressing a XBP1-luciferase 
reporter in which luciferase is expressed only when XBP1 is spliced by activated 
IRE1 (Spiotto et al, 2010; Tsai & Weissman, 2010), which also provides a useful 
mouse model to address the role of IRE1-XBP1 in VAPB-mediated breast tumor 
proliferation and invasion. 
 
VAPB’s therapeutic potential in breast cancer? 
Our data presented thus far demonstrate that VAPB functions to increase 
breast tumor cell and invasion through enhanced AKT activity. This pathway is 
commonly dysregulated in breast cancer and often promotes resistance to 
current therapies (Miller et al, 2011), such as those that target HER2. Treatment 
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of VAPB-expressing cells with two different PI3K-AKT inhibitors reduced 
spheroid size to a greater extent than non-VAPB-expressing cells. This suggests 
that VAPB is more dependent on AKT signaling and may increase sensitivity to 
AKT inhibitor-based therapies. Another step to determine the therapeutic 
potential of targeting AKT in VAPB-expressing cancers is to correlate high VAPB 
expression with elevated AKT activity in human breast tumor samples. The 
results from such studies would help stratify patient populations into those that 
would benefit most from AKT-targeted therapies. 
Moreover, our results also demonstrate that VAPB enhances secretory 
vesicle transport. Secretion of growth factors, cytokines, matrix 
metalloproteinases, as well as delivery of receptors to the cell surface, facilitate 
tumor growth and invasion (Hanahan & Weinberg, 2011). The high demand for 
such proteins to maintain tumor growth provides unique opportunities for 
targeting vesicle trafficking in cancer therapeutics (Wright, 2008).  
Furthermore, our observations that high VAPB expression correlates with 
poor prognosis and the ability to detect its secreted form (MSP) in human serum 
(Tsuda et al, 2008) suggests that VAPB can be used as a potential biomarker in 
breast cancer diagnostics, both in tumor tissue and in serum. Despite numerous 
advances in mechanism-based therapies, breast cancer morbidity rates remain 
high. Therefore, it is imperative that alternate cellular processes, such as those 
modulated by VAPB, be further investigated as potential targets for breast cancer 
chemotherapy. 
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Final Remarks 
 
Since the cloning of VAPB 15 years ago, significant progress has been 
made to understand the importance of VAPB in multiple cellular processes. The 
data presented in my dissertation demonstrate the impact of VAPB expression in 
human breast cancer through genetic, biochemical analyses using 3-dimensional 
cell culture and animal models. We suggest two mechanisms by which VAPB 
affects breast tumor cells: (1) increased AKT activation and (2) enhanced 
secretory vesicle transport. It is likely that both pathways converge to support 
VAPB function in tumor cells. The diversity of VAPB functions and their impact on 
cellular processes such as secretory protein transport, lipid metabolism and lipid 
transfer represent several pathways that could be potentially exploited by breast 
tumor cells to promote growth and invasion. We anticipate that new insights 
regarding how VAPB promotes breast cancer will emerge in the coming years as 
well as clarify the role of the extracellular, secreted form of VAPB. More 
importantly, this work will trigger renewed interest regarding VAPB in other 
cancer types in the hope that future mechanistic studies will help understand 
VAPB’s role in various human pathologies. 
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